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Summary
Summary (English) 
Schizophrenia and bipolar disorder often have devastating impacts on the lives of affected 
individuals. The etiology of these disorders has yet to be fully understood. Heritability 
estimates from twin studies are high for schizophrenia and bipolar disorder (> 80 % (Bienvenu 
et al., 2011)), highlighting potentially large genetic influences. Findings from genome-wide 
association studies (GWAS) support the highly polygenic architecture of both disorders. 
Extraordinarily large samples are required in GWAS, owing to the small effect sizes of the 
individual genetic variants, and a large multiple testing burden. 
Although represented as different categorical entities in current diagnostic systems, both 
genetic and phenotypic overlap has been shown for schizophrenia and bipolar disorder. 
These findings constitute the rationale for transdiagnostic studies with hierarchically (Kotov et 
al., 2017) and dimensionally (Cuthbert and Insel, 2010; Insel et al., 2010) measured 
phenotypes. Furthermore, both disorders are characterized by a heterogeneous course of 
illness. The combination of illness course and genetic background may provide insights to 
define more homogeneous, treatment-specific subgroups (“stratified medicine”, (Kapur et al., 
2012)). 
In the presented work, two strategies were applied to investigate the genetic underpinnings 
of quantitative indicators of the course of illness in patients with severe mental disorders. In 
the first publication, our prospective transdiagnostic longitudinal PsyCourse study is 
introduced in terms of study design and a first symptom-specific characterization of the 
sample. Over an 18 months period data were collected from patients with disorders from the 
affective-to-psychotic continuum. These data included a comprehensive dimensional 
assessment of psychopathology and general functioning combined with the collection of 
peripheral blood samples, providing a unique resource to research the complex relationship 
between psychopathology and biology. As expected, predominantly psychotic patients 
showed more pronounced psychotic symptoms and a lower general functioning over time as 
well as a higher polygenic load with schizophrenia risk alleles compared to predominantly 
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affective patients. The level of depressive as well as manic symptoms, however, did not differ 
significantly between groups over time. These findings support a dimensional rather than a 
categorical model of psychiatric disorders. 
- Budde M, Anderson-Schmidt H, Gade K,[…], Falkai P, Schulze TG, Heilbronner
U. 2019a. A longitudinal approach to biological psychiatric research: The
PsyCourse study. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 180: 89–
102.
From both ethical as well as economic perspectives it is important to make optimal use of 
already existing data. Although large from a clinical perspective, the size of available data on 
quantitative phenotypes in psychiatric research is often limited from a genetic point of view. 
Consequently, there is a need for data analysis methods with reduced multiple testing 
burden in order to successfully use samples moderate in size. In the second publication, we 
did just that by combining powerful statistical methods using prior knowledge on biological 
function and dependence of genotypes. Specifically, we investigated functional outcome as 
an important cross-sectional indicator of course of illness in bipolar disorder patients in two 
independent samples and identified a significantly associated locus on chromosome 15. This 
study confirms the ability of cross-sectional data of moderate sample size to provide 
important contributions to psychiatric genetic research.  
- Budde M, Friedrichs S, Alliey-Rodriguez N, […], Rietschel M, Schulze TG,
Malzahn D. 2019b. Efficient region-based test strategy uncovers genetic risk
factors for functional outcome in bipolar disorder. Eur.
Neuropsychopharmacol. 29: 156–170.
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Zusammenfassung (German) 
Schizophrenie und bipolare Störungen haben oft verheerende Folgen für das Leben der 
Betroffenen. Die Ätiologie dieser Erkrankungen ist bisher nicht vollständig aufgeklärt. 
Zwillingsstudien haben Heritabilitätsschätzungen von über 80 % für Schizophrenie und 
bipolare Störungen ergeben (Bienvenu et al., 2011) und sprechen somit für einen deutlichen 
Einfluss genetischer Faktoren. Die Ergebnisse genomweiter Assoziationsstudien (GWAS) 
legen einen hoch polygenen Charakter dieser Erkrankungen nahe. Für ebendiese GWAS 
werden aufgrund der kleinen Effekte der einzelnen genetischen Varianten sowie des 
multiplen statistischen Testens außerordentlich große Stichproben benötigt.  
Auch wenn Schizophrenie und bipolare Erkrankungen in aktuellen Diagnosesystemen als 
unterschiedliche kategoriale Einheiten abgebildet sind, konnten Überschneidungen sowohl 
auf genetischer als auch auf phänotypischer Ebene gezeigt werden. Diese Befunde bilden 
die Basis für diagnoseübergreifende Studien mit hierarchischen (Kotov et al., 2017) und 
dimensionalen (Cuthbert and Insel, 2010; Insel et al., 2010) Phänotypen. Darüber hinaus 
weisen Patienten mit beiden Erkrankungen sehr heterogene Krankheitsverläufe auf. Die 
Kombination von Verlauf und genetischem Hintergrund könnte daher ein Schlüssel sein, um 
homogenere, behandlungsrelevante Subgruppen zu finden (“stratified medicine”, (Kapur et 
al., 2012)). 
In dieser Arbeit wurden zwei verschiedene Strategien angewendet, um die genetischen 
Grundlagen von Indikatoren des Krankheitsverlaufs bei Patienten mit schweren psychischen 
Erkrankungen zu untersuchen. In der ersten Publikation wird unsere prospektive 
diagnoseübergeifende longitudinale PsyCourse Studie vorgestellt und eine 
symptomspezifische Charakterisierung der Stichprobe vorgenommen. Über einen Zeitraum 
von 18 Monaten wurden bei Patienten aus einem Kontinuum von affektiven hin zu 
psychotischen Erkrankungen Daten erhoben. Diese Datenerhebung beinhaltete eine 
umfassende dimensionale Erfassung der Psychopathologie sowie des allgemeinen 
Funktionsniveaus und die Entnahme von Blutproben. Somit wurde eine bedeutsame 
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Ressource geschaffen, um komplexe Beziehungen zwischen Psychopathologie und ihren 
biologischen Grundlagen zu erforschen. Wie erwartet zeigten Patienten mit überwiegend 
psychotischen Erkrankungen im Vergleich zu denen mit überwiegend affektiven 
Erkrankungen im Studienverlauf stärker ausgeprägte psychotische Symptome, ein 
niedrigeres Funktionsniveau und eine höhere polygene Belastung mit Risikoallelen für 
Schizophrenie. Die Belastung mit depressiven sowie manischen Symptomen unterschied 
sich dagegen im Studienverlauf nicht zwischen den Gruppen. Diese Ergebnisse stützen eher 
ein dimensionales als ein kategoriales Modell für psychiatrische Erkrankungen.  
- Budde M, Anderson-Schmidt H, Gade K,[…], Falkai P, Schulze TG, Heilbronner
U. 2019a. A longitudinal approach to biological psychiatric research: The
PsyCourse study. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 180: 89–
102.
Sowohl aus ethischen als auch aus ökonomischen Gesichtspunkten ist es wichtig, bereits 
existierende Daten optimal zu nutzen. Auch wenn sie aus klinischer Perspektive groß 
erscheinen, sind die Datensätze zu quantitativen Phänotypen für psychiatrisch-genetische 
Analysen oft verhältnismäßig klein. Daher werden statistische Methoden benötigt, bei denen 
das Problem des multiplen Testens verringert wird, um auch kleinere Stichproben erfolgreich 
nutzen zu können. In der zweiten Publikation haben wir statistische Methoden so kombiniert, 
dass vorhandenes Wissen zu biologischen Funktionen von genetischen Varianten sowie zur 
Abhängigkeit zwischen Genotypen optimal genutzt werden konnte. Konkret haben wir das 
Funktionsniveau als wichtigen Querschnittsindikator für den Krankheitsverlauf bei Patienten 
mit bipolaren Störungen in zwei unabhängigen Stichproben untersucht und dabei einen 
signifikant assoziierten Locus auf Chromosom 15 identifiziert. Diese Studie bestätigt, dass 
auch Querschnittsdaten aus weniger großen Stichproben wichtige Beiträge zur 
psychiatrisch-genetischen Forschung liefern können. 
- Budde M, Friedrichs S, Alliey-Rodriguez N, […], Rietschel M, Schulze TG,
Malzahn D. 2019b. Efficient region-based test strategy uncovers genetic risk
factors for functional outcome in bipolar disorder. Eur.
Neuropsychopharmacol. 29: 156–170.
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Introduction 
The polygenic architecture of schizophrenia and bipolar disorder 
Schizophrenia (SZ) and bipolar disorder (BD) are severe mental illnesses with devastating 
impact on the lives of affected individuals. Currently the lifetime prevalence is estimated at 
1 % for SZ (Kahn et al., 2015) and up to 2.4 % for BD (Merikangas et al., 2011). In the Global 
Burden of Disease Study 2016, SZ was ranked among the top 20 and BD among the top 30 
causes for years lived with disability, a measurement for the burden of a disease (GBD 2016 
Disease and Injury Incidence and Prevalence Collaborators, 2017). Despite considerable 
progress in research, the etiology of these disorders has yet to be fully understood.  
Biological-psychiatric research seeks a better understanding of disease mechanisms with the 
ultimate goal of developing more effective treatments and tailoring treatments to the specific 
needs of an individual. However, a truly “personalized medicine” still seems far off. As 
psychiatric disorders are characterized by heterogeneous phenotypes, it would be 
immensely helpful to have biomarkers or other indicators to broadly stratify patients into 
treatment-specific subgroups (Kapur et al., 2012). Given the wealth of studies in the field of 
biological psychiatry, this approach of “stratified medicine” seems achievable (Kapur et al., 
2012). Naturally, pharmacogenetics is the branch of psychiatric genetics currently receiving 
most attention in clinical practice (Moreno-De-Luca et al., 2018). The goal of 
pharmacogenetics is to find genetic variants that can predict the therapeutic response and/or 
adverse reactions of an individual to a specific medication (Moreno-De-Luca et al., 2018). 
Despite great research efforts, e.g. into genetics of lithium response in BD patients (for a 
review see (Budde et al., 2017a)), a task force of the International Society of Psychiatric 
Genetics (ISPG) stated recently that the evidence to support widespread use of 
pharmacogenetic tests is still inconclusive (International Society of Psychiatric Genetics, 
2019). Likewise, to this day, only two clinical implementations are supported by the German 
Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN): (1) testing of 
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CYP2D6 prior to prescription of tricyclic antidepressants and (2) determining the HLA-B*1502 
genotype in patients of Asian origin before using carbamazepine (Müller et al., 2018). 
Severe psychiatric disorders like SZ and BD aggregate within families (Gottesman et al., 
2010; Lichtenstein et al., 2009). The heritability of both disorders, i.e. the proportion of 
phenotypic variation that is accounted for by genetic variation, is estimated at over 80% in 
twin studies (Bienvenu et al., 2011). To characterize these genetic components, early 
molecular genetic studies like linkage studies and candidate gene association studies were 
conducted, albeit with modest success owing to the complex genetic architecture of 
psychiatric traits. Technical progress has led to genome-wide association studies (GWAS) 
which use hypothesis-free analysis methods usually carried out in a sample of unrelated 
individuals. The first GWAS in the field of psychiatry was published by the Wellcome Trust 
Case Control Consortium (WTCCC) in 2007 (Wellcome Trust Case Control Consortium, 
2007). In psychiatric genetics, mostly qualitative binary outcome phenotypes, particularly 
case-control comparisons, have been analyzed (Andlauer et al., 2018). In case-control 
GWAS, minor allele frequencies (MAF), i.e. the frequency at which the second most frequent 
allele occurs in a given sample, of millions of single nucleotide polymorphisms (SNPs) are 
compared between cases and controls. These studies require large sample sizes, for two 
main reasons. Firstly, SNPs explored in GWAS are common SNPs with a minor allele 
frequency of usually ≥ 1 %. These common SNPs are likely to stem from ancient mutations 
(Sham and Cherny, 2011) and are expected to have relatively small individual effects. If an 
allele had large negative effects on individuals’ fitness, allele frequency would have been 
reduced by natural selection throughout evolution (Wray et al., 2013). In fact, the individual 
effects of common SNPs have been empirically found to be relatively small. More precisely, 
almost all variants associated with SZ or BD on a genome wide-significant level show odds 
ratios (OR) < 1.2 (Pardiñas et al., 2018; Stahl et al., 2019). The only exception is the top 
finding of the SZ GWAS, a locus within the major histocompatibility complex (OR = 1.28 
(Pardiñas et al., 2018)). Therefore, large samples are needed to achieve sufficient statistical 
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power to detect the small effects of individual SNPs. Secondly, simultaneous statistical 
analysis of millions of SNPs in a GWAS makes stringent adjustment of significance level 
necessary in order to avoid an excess of false-positive SNPs (Type-I error cumulation). 
Therefore, in samples of European descent, only associations with corresponding p-values of 
p ≤ 5×10-8 are considered genome-wide significant (Andlauer et al., 2018; Sham and Purcell, 
2014). The latter equals a Bonferroni correction for 1 million tests and reflects the number of 
statistically independent genetic loci (Andlauer et al., 2018; Sham and Purcell, 2014).  
Major technical advances that led to decreasing costs for genotyping have shaped the field 
of psychiatric genetics since the first GWAS by the WTCCC. Big consortia like the Psychiatric 
Genomics Consortium (PGC) have been formed, allowing for the large sample sizes 
required. This development has yielded great successes. The latest GWAS reported 145 
genome-wide significant loci associated with SZ (Pardiñas et al., 2018) and 30 loci 
associated with BD susceptibility (Stahl et al., 2019). While early GWAS were unable to 
produce replicable findings, the last years have seen more success with loci replicating 
across multiple GWAS of different cohorts. (see e.g. (Budde et al., 2017b) for a review of 
GWAS results in BD). This development towards more robust findings will continue as 
sample sizes grow.  
It is important to note that results from GWAS can be utilized for far more than just loci 
identification (Maier et al., 2018). Equally important, GWAS can help us to unravel the 
genetic architecture of complex diseases. As noted earlier, overall heritability estimates of SZ 
and BD from twin studies are high (> 80 % (Bienvenu et al., 2011)). Only a small fraction of 
this variation is explained by the accumulated effects of genome-wide significant loci, e.g. 
3.4 % for SZ (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014). 
This phenomenon is called “missing heritability” (Maher, 2008). However, by means of 
GWAS data, so called SNP-heritabilities for certain traits can be estimated i.e. the proportion 
of phenotypic variance explained by genotyped SNPs (Maier et al., 2018). A recent 
publication reported SNP-heritabilities of 20 % for BD and 25 % for SZ (Brainstorm 
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Consortium et al., 2018). SNP-heritability estimates are typically lower than heritability 
estimates from twin and family studies for several reasons (Maier et al., 2018). For example, 
genetic effects might be explained by influences of rare variants with large effects not 
covered by genotyping chips, non-additive genetic effects or epigenetic mechanisms. 
However, SNP-heritability estimates are larger than the heritability that can be explained so 
far by genome-wide significant SNPs alone, suggesting that the “missing heritability” is 
actually in part “hidden heritability” and that the number of genome-wide significant loci will 
continue to increase with even bigger samples (Wray et al., 2014). Indeed a linear 
relationship between the increase of sample size and the increase in the number of loci 
reaching genome-wide significance was observed for complex traits in sample sizes above a 
critical number (“inflection point”, (Panagiotou et al., 2013)). For example, in SZ with each 
1,000 additional cases added beyond a base sample size of approximately 13-18,000 cases 
(inflection point), one would expect to find approximately four new genome-wide significant 
markers (Levinson et al., 2014). This implicates that these traits are highly polygenic. Thus, 
the overall genetic influence consists of small effects of thousands of genetic variants. 
GWAS can also reveal shared genetic factors between traits by enabling the calculation of 
genetic correlations (rg) between traits. “Two traits are genetically correlated, if there is a 
correlation between the true effect sizes of SNPs affecting the two traits, or in other words, 
when, on average, SNPs have directionally similar effects on two traits” (Maier et al., 2018). 
Severe mental illnesses are significantly genetically correlated (Selzam et al., 2018). The 
highest correlations were observed between SZ and BD with rg estimates of up to 0.74 
(Consortium Cross-Disorder Group of the Psychiatric Genomics et al., 2019; Selzam et al., 
2018), highlighting the genetic overlap between these disorders.  
Additionally, GWAS summary statistics allow for the calculation of polygenic risk scores 
(PRS). PRS are a robust estimate of the polygenic load an individual carries for a certain 
trait, for example SZ or BD (Purcell et al., 2009; Wray et al., 2014). A PRS is the sum of 
independent risk and protective minor alleles an individual carries weighted by their 
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respective effect sizes. Here it is important to note that the information regarding genetic 
marker selection, effect sizes and direction of effects of alleles comes from an independent 
discovery GWAS. This means that the sample in which PRS are calculated must not be part 
of the GWAS that provides the summary statistics used for PRS calculation. While heritability 
is estimated on the population level and does not allow for inference of individual genetic 
risks, PRS represent the polygenic load of individuals for a certain phenotype. PRS are often 
applied in research to study the genetic overlap between diseases. Results support the 
notion of a partially overlapping (Cross-Disorder Group of the Psychiatric Genomics 
Consortium, 2013; Purcell et al., 2009), yet also specific (Ruderfer et al., 2014) polygenic 
basis of SZ and BD. Furthermore, the association of PRS with disease-relevant quantitative 
phenotypes in patients and the general population can be explored. For example, some 
studies report a negative association between schizophrenia polygenic risk scores (SZ-PRS) 
and cognitive impairment (for a review, see (Schaupp et al., 2018)), which is a core feature of 
severe psychiatric illnesses. Interestingly, SZ-PRS have also been associated with important 
indicators of severity of illness, namely chronicity (Meier et al., 2016), treatment resistance 
(Frank et al., 2015), hard to treat symptoms like increased negative symptoms (Bipolar 
Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2018) 
and religious delusions (Anderson-Schmidt et al., 2019) in SZ. Furthermore, SZ-PRS has 
been associated with psychotic features in BD (Bipolar Disorder and Schizophrenia Working 
Group of the Psychiatric Genomics Consortium, 2018). These findings indicate a dose-
response relationship between polygenic load and illness severity.  
Accuracy of PRS highly depends on the statistical power of the respective discovery GWAS 
(Dudbridge, 2013). Even though PRS are a robust estimate of a person’s genetic load of 
common SNPs, they are not yet suitable for individual risk prediction in a clinical context 
owing to their limited predictive accuracy. The two biggest studies to date report that ~7 % 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014) or rather 
5.7 % (Pardiñas et al., 2018) of the variation on the liability scale to SZ across samples could 
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be explained by SZ-PRS. Comparably, bipolar disorder polygenic risk scores (BD-PRS) 
based on the latest GWAS on BD, explain ~ 4 % of the variation on the liability scale to BD 
across samples (Stahl et al., 2019). Since GWAS in the field of psychiatry have been mostly 
case-control comparisons, PRS for important quantitative phenotypes are still warranted.  
 
Psychiatric diagnoses: categorical vs. dimensional approaches 
In 1899, the German psychiatrist Emil Kraepelin divided affective and psychotic disorders in 
adulthood into manic-depressive illness and dementia praecox (Kraepelin, 1899). The latter 
was characterized by deficits in intellectual functioning as well as deterioration and a poorer 
prognosis. To this day, BD and SZ are represented as separate categorical entities in 
common diagnostic systems like the Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-5) and the 10th revision of the International Statistical Classification of 
Diseases and Related Health Problems (ICD-10). However, robust findings of a shared 
genetic overlap between SZ and BD have challenged this dichotomous view from a biological 
perspective. In addition, a phenotypic overlap between these disorders exists. Individuals 
suffering from SZ often experience affective symptoms and affective episodes in BD patients 
can be accompanied by psychotic symptoms. Both groups of patients suffer from stable 
cognitive impairment outside of acute illness episodes (Budde and Schulze, 2014; 
Heilbronner et al., 2016) albeit – as already observed by Kraepelin – to a different degree 
(Stefanopoulou et al., 2009; Vöhringer et al., 2013). 
To this day, there are no biomarkers of psychiatric disease. Hence psychiatric diagnoses are 
based on phenotypic syndromes and therefore do not necessarily represent biologically 
distinct entities. Both biological and phenotypic overlap indicate that dimensionally defined 
diagnoses might map the nature of psychiatric diseases more precisely than categorical ones 
(Craddock and Owen, 2010; Guloksuz and van Os, 2018). Spectrum phenotypes have been 
included in the DSM 5 for autism and substance abuse, but not yet for SZ and BD. Along this 
12
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line, alternative concepts of hierarchically and dimensionally measured phenotypes have 
been established by the National Institute of Mental Health (NIMH) Research Domain Criteria 
framework (RDoC; (Cuthbert and Insel, 2010; Insel et al., 2010)) and the Hierarchical 
Taxonomy of Psychopathology system (hiTOP; (Kotov et al., 2017)).  
The course of psychiatric disorders 
Like all severe psychiatric disorders, SZ (an der Heiden and Häfner, 2000; Carpenter and 
Kirkpatrick, 1988; Heilbronner et al., 2016) and BD (Angst and Sellaro, 2000; Marneros and 
Brieger, 2002) show a heterogeneous course of illness. Even instability of diagnoses over 
time is a common phenomenon in everyday clinical practice. In both disorders, there is a 
spectrum of courses ranging from mild forms with few acute episodes and full remission in 
between to chronic, treatment resistant conditions. The disease course is of utmost 
importance to the patient and the clinician. Therefore, studying its determinants is clinically 
highly relevant. As described earlier, already Kraepelin’s categorization of adult psychiatric 
illnesses was based on his observations of the course of disease.  
So far, little is known about biological differences between types of disease courses. 
However, some indicators of a poorer course have been found to be familial including 
substance abuse, alcoholism, psychosis, history of suicide attempt, and the level of social 
functioning in BD (Schulze et al., 2006) and negative symptoms, mania and the deficit 
syndrome of SZ in psychotic disorders (Peralta et al., 2016). Moreover, as highlighted above, 
there seems to be a dose-response-relationship between SZ polygenic load and indicators of 
a poorer disease course. Therefore it seems reasonable that course might be a key to find 
more homogeneous subgroups of patients for “stratified medicine”. 
Combining biological information and clinical course may reveal fundamental similarities and 
differences between SZ and BD. An obvious way to investigate the course of an illness is to 
conduct a prospective longitudinal study (own contribution publication #1: (Budde et al., 
13
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2019a)). Complementary, indicators of disease course can be assessed retrospectively (own 
contribution publication #2: (Budde et al., 2019b)).  
Studies on transdiagnostically measured quantitative psychiatric phenotypes in general and 
longitudinal studies in particular are very valuable, yet still limited in number and sample 
sizes since they are complex and expensive. Therefore, the PsyCourse study by our group 
(publication #1: (Budde et al., 2019a)) provides an especially valuable resource for studying 
the biological underpinnings of the course of severe psychiatric disorders. So far, the 
PsyCourse resource has given rise to several publications, including research on age at 
onset in BD (Kalman et al., 2019), religious delusions in SZ (Anderson-Schmidt et al., 2019), 
the genetic relationship between educational attainment and cognition in mental illnesses 
(Comes et al., 2019) and on the interplay of Hdac1 variants with early life stress (Bahari-
Javan et al., 2017). Moreover PsyCourse has contributed data to larger consortia (Bipolar 
Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2018; 
Consortium Cross-Disorder Group of the Psychiatric Genomics et al., 2019; Drange et al., 
2019; Mullins et al., 2019), and will continue to do so.  
Unfortunately, so far there is no agreement on, nor harmonization of, assessment scales that 
should preferably be used across studies. This complicates the search for replication 
samples for biologically important quantitative phenotypes beyond case-control status (Kapur 
et al., 2012). Nevertheless, as previously discussed, sample size is crucial in psychiatric 
genetics. Therefore, in parallel to setting up transdiagnostic projects with dimensional 
phenotypes, it is highly desirable to find new ways to make the best use of already existing 
data (publication #2: (Budde et al., 2019b)). The latter is important both from ethical as well 
as economic perspectives.  
This dissertation combines two publications that apply different strategies to explore 
phenotypic and genetic correlates of the course of SZ and BD via quantitative phenotypes.  
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Publication #1: A longitudinal approach to biological psychiatric research: The 
PsyCourse study (Budde et al., 2019a) 
The PsyCourse Study is a multicenter, longitudinal, transdiagnostic study on the course of 
severe mental illnesses funded by the Deutsche Forschungsgemeinschaft (DFG) led by Prof. 
Thomas G. Schulze and Prof. Peter Falkai. A dimensional assessment of psychopathology 
over a time span of 18 months was combined with the collection of biomaterials in patients 
from the affective-to-psychotic continuum, providing a unique resource to research the 
complex relationship between psychopathology and biology. From the beginning of the 
project on, I have contributed in many ways: to the data protection concept (Demiroglu et al., 
2012), in the development of the phenotype database, by recruitment of study participants 
and managing cooperations with other study centers, including database maintenance and 
quality control of the data. In Budde et al. (2019a), the design of the PsyCourse study as well 
as a first characterization of the sample is presented. Patients were grouped into those with 
predominantly affective (n = 367 individuals; diagnoses: BD and recurrent major depressive 
disorder) vs. those with predominantly psychotic (n = 524 individuals; diagnoses: SZ, 
schizoaffective disorder, schizophreniform disorder and brief psychotic disorder) symptoms. 
Depressive (30 Item Inventory of Depressive Symptomatology, IDS-C30), manic (Young 
Mania Rating Scale, YMRS) and psychotic (Positive and Negative Syndrome Scale, PANSS, 
positive scale) symptoms as well as global functioning (Global Assessment of Functioning 
score, GAF) were then analyzed over time in these two groups of patients using linear mixed 
models. While the degree of psychotic symptoms and global functioning differed between 
groups, there were no significant differences in both manic and depressive symptoms. These 
findings support a dimensional rather than a categorical model of psychiatric diseases on a 
phenotypic level. Diagnostic groups also differed regarding their SZ-PRS. SZ-PRS 
significantly explained variability between these two diagnostic groups (Nagelkerke’s 
R² ~ 1%). As expected, higher SZ-PRS increased the odds of being in the “predominantly 
psychotic” group. 
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Publication #2: Efficient region-based test strategy uncovers genetic risk factors for 
functional outcome in bipolar disorder (Budde et al., 2019b)  
Although there is a pressing need for longitudinal studies, it is equally important to make 
optimal use of already existing data. This work was a joint project in cooperation with Dr. 
Dörthe Malzahn from the Department of Genetic Epidemiology in Göttingen, who conducted 
the statistical analyses, and groups from Bonn and Mannheim as well as the Bipolar 
Genomics Consortium (USA), who contributed data. We explored genetic effects on global 
functioning (GAF score), which measures the overall psychological, social and occupational 
functioning of a subject, in two independent samples of BD patients (N = 1,592 in total). The 
GAF was assessed during outpatient treatment as an indicator of disease course outside of 
acute episodes. Although large from a clinical perspective, the sample does not provide 
enough power for a GWAS. To overcome these sample size limitations, we combined 
powerful statistical methods into a functionally-informed efficient region-based test strategy 
(FIERS). FIERS uses prior knowledge on biological function and dependence of genotypes 
to reduce the multiple-testing burden and provides improved sensitivity and specificity to 
detect consistent effects across studies. With this method, a significantly associated locus on 
chromosome 15 (hg38: chr15: 48965004-49464789 bp) was identified with consistent effect 
strength between samples. Haplotype analysis revealed risk and protective haplotypes for 
functional outcome on the most strongly associated SNPs. Plausible biological candidates 
related to the associated region are a CTCF binding site (regulatory element), the genes 
COPS2, EID1 and SHC4, which are known to be involved in neuronal differentiation and 
function, as well as DTWD1, which is relevant for psychopharmacological side effects. This 
study demonstrates that an efficient combination of statistical methods and contextual 
knowledge enables the field to gain mechanistic insight into the biology underlying important 
quantitative phenotypes.  
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In current diagnostic systems, schizophrenia and bipolar disorder are still conceptualized as distinct
categorical entities. Recently, both clinical and genomic evidence have challenged this Kraepelinian
dichotomy. There are only few longitudinal studies addressing potential overlaps between these
conditions. Here, we present design and first results of the PsyCourse study (N5891 individuals
at baseline), an ongoing transdiagnostic study of the affective-to-psychotic continuum that com-
bines longitudinal deep phenotyping and dimensional assessment of psychopathology with an
extensive collection of biomaterial. To provide an initial characterization of the PsyCourse study
sample, we compare two broad diagnostic groups defined by the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition (DSM-IV) classification system, that is, predominantly affective
(n5367 individuals) versus predominantly psychotic disorders (n5524 individuals). Depressive,
manic, and psychotic symptoms as well as global functioning over time were contrasted using lin-
ear mixed models. Furthermore, we explored the effects of polygenic risk scores for schizophrenia
on diagnostic group membership and addressed their effects on nonparticipation in follow-up vis-
its. While phenotypic results confirmed expected differences in current psychotic symptoms and
global functioning, both manic and depressive symptoms did not vary between both groups after
correction for multiple testing. Polygenic risk scores for schizophrenia significantly explained part
of the variability of diagnostic group. The PsyCourse study presents a unique resource to research
the complex relationships of psychopathology and biology in severe mental disorders not confined
to traditional diagnostic boundaries and is open for collaborations.
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1 | INTRODUCTION
The Kraepelinian dichotomy, which postulates adult affective and psy-
chotic disorders to be separate categorical entities, still has a major
influence on Western psychiatry. It therefore remains in current diag-
nostic systems such as the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-5). This dichotomous view has recently
been questioned by biological research (O’Donovan & Owen, 2016).
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In addition, there is extensive overlap of symptoms between schizo-
phrenia (SZ) and bipolar disorder (BD) as observed in clinical day-to-day
reality (Murray et al., 2004). Traditional categorical nosological systems
have therefore been fundamentally challenged during the past years.
Alternative concepts of hierarchically and dimensionally measured phe-
notypes have been put forward by the NIMH Research Domain Criteria
(RDoC; Cuthbert & Insel, 2010; Insel et al., 2010) and the Hierarchical
Taxonomy of Psychopathology (HiTOP; Kotov et al., 2017), the former
emphasizing the need for biologically informed domains early on. To
this end, genetics have often played an important role in redefining psy-
chiatric diagnoses (Robins & Guze, 1970). More recently, findings
regarding an overlapping but distinct genetic basis of SZ and BD in both
family (Lichtenstein et al., 2009) and molecular genetic studies (Cross-
Disorder Group of the Psychiatric Genomics Consortium, 2013; For-
stner et al., 2017; Purcell et al., 2009), have accelerated the momentum
toward dimensionally defined diagnosis (Craddock & Owen, 2010) of
severe mental disorders. Even though spectrum phenotypes have been
introduced in the DSM-5 in the areas of autism and substance use, this
modern diagnostic approach has not been applied to SZ and BD. How-
ever, as outlined above, there are several compelling reasons for the
introduction of a psychosis spectrum disorder (for a detailed discussion
see Guloksuz & van Os, 2017). There is thus a pressing need to incorpo-
rate this biological information into future diagnostic systems.
Against this background, addressing two important issues might
pave the way for a successful research into this matter: First, longitudi-
nal research is necessary to capture variation over time. Pronounced
heterogeneity in the longitudinal course of both SZ (e.g., Carpenter &
Kirkpatrick, 1988; Heilbronner, Samara, Leucht, Falkai, & Schulze,
2016) and BD (e.g., Angst, 1978) exists. Overlap of symptoms, comor-
bidity and instability of diagnoses over time occur frequently in every-
day clinical practice. Thus, just as subtypes of traditionally defined
nosological categories emerged by examining their clinical course (e.g.,
Bleuler, 1968), similarities and differences between traditionally
defined SZ and BD may emerge when a combination of biological
information and clinical course is considered. While only few modern
longitudinal studies of severe mental illnesses exist, the longitudinal
course of affective disorders, such as BD, has received particularly little
attention to date (Pfennig et al., 2017). Second, a major emphasis on
phenomics is needed, “the systematic study of phenotypes on a
genome-wide scale” (Bilder et al., 2009). In an age in which genomic
and other high-throughput data can be obtained relatively inexpen-
sively and rapidly, a major challenge is to obtain extensive high-quality
phenotype data. Such data are required to establish meaningful geno-
type–phenotype relationships, and will ultimately lead to biologically
informed patient stratification (Kapur, Phillips, & Insel, 2012).
The aim of this communication is to introduce the PsyCourse
study, a longitudinal study of severe mental disorders on the affective-
to-psychotic continuum, which aims to address these issues. Deep phe-
notyping is combined with an extensive collection of biological material
at every measurement point, enabling the combination of multilevel
omics and longitudinal clinical data. Specifically, current symptomatol-
ogy, cognitive status, and self-report measures are assessed at every
measurement point, interspersed with the collection of relevant cross-
sectional data (see Supporting Information Table 1).
Here, we provide an initial characterization of the PsyCourse study
sample. First, we present longitudinal data on positive, depressive, and
manic symptoms as well as data on global psychosocial functioning of
the clinical participants of the PsyCourse study. We compare these var-
iables between two broad diagnostic groups within the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
framework, defined as psychotic and affective, by their predominant
symptoms. In addition, as proof of principle of the PsyCourse sample’s
potential for genomic analyses, we use polygenic risk scores (PRS) for
SZ (SZ-PRS) for a first biological characterization of these diagnostic
groups. PRS are a method for estimation of the polygenic load of
common risk alleles an individual carries for a certain trait or disorder
(Purcell et al., 2009); for overview see Wray et al. (2014; in this case
for SZ). Findings from PRS analyses support the notion of both
overlapping (Purcell et al., 2009) and specific (Ruderfer et al., 2014)
genetic backgrounds of SZ and BD as well as the continuum model of
psychosis (Tesli et al., 2014). To study genetic overlap between
disorders by means of PRS, it is usually analyzed whether PRS for one
disorder, for example, SZ, can successfully predict case–control status
for other traits, for example BD (Cross-Disorder Group of the
Psychiatric Genomics Consortium, 2013; Purcell et al., 2009). Another
approach, focusing on the specific genetic backgrounds of SZ and BD,
was used by Ruderfer et al. (2014) who created a PRS for the
discrimination between SZ and BD. Here, we used SZ-PRS because the
available discovery genome-wide association study (GWAS) comparing
SZ patients and controls is based on a substantially larger sample
(N536,989 patients vs. N5113,075 controls; Ripke et al., 2014) than
the largest published GWAS comparing BD and controls (N513,902
patients vs. N519,279 controls; Charney et al., 2017). Unlike the stud-
ies described above, we directly explore to what extent SZ-PRS can dif-
ferentiate between two groups of patients in the PsyCourse study,
predominantly psychotic and affective participants. As longitudinal
research inevitably leads to attrition, selective dropout of subgroups of
study participants is a major challenge. This is especially important as it
is well-known that demographic variables like age, sex, socioeconomic
status as well as emotional and behavioral problems are associated
with attrition (de Graaf, van Dorsselaer, Tuithof, & ten Have, 2013;
Wolke et al., 2009). Notably, a recent study found higher SZ-PRS to be
associated with nonparticipation over time in a population-based
cohort study (Martin et al., 2016). Therefore, we also present analyses
on possible demographic and illness-related predictors of dropout and
further explore the association of SZ-PRS and dropout in our patient
sample. A selective dropout of participants with a specific biological
profile would have important implications for longitudinal biological
research in psychiatry.
2 | MATERIALS AND METHODS
2.1 | Properties of the PsyCourse study
PsyCourse is an ongoing multicenter study, conducted by a network of
clinical sites in Germany and Austria. At the time of writing, 18
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different clinical centers participated in data collection of clinical partic-
ipants, two of which additionally collect data from nonclinical (control)
individuals. The study protocol was approved by the respective ethics
committee for each study center and was carried out following the
rules of the Declaration of Helsinki of 1975, revised in 2008. Initially,
the project was approved by the Ethics Committee of the University
Medical Center Goettingen. Some clinical centers were teaching hospi-
tals of the University Medical Center Goettingen, and were thus cov-
ered by this initial approval. For those clinical sites that were not
covered, we obtained additional approval from the respective Ethics
Committees. For all centers, these were (clinical centers in parenthe-
ses): Ethics Committees of the University Medical Center Goettingen
(UMG Goettingen, Bad Zwischenahn, Eschwege, Asklepios Specialized
Hospital Goettingen, Hildesheim, L€uneburg, Liebenburg, Osnabr€uck,
Rotenburg, Tiefenbrunn, Wilhemshaven), Medical Faculty of the LMU
Munich (Munich and Augsburg), Medical Faculty of the RU Bochum
(Bochum), Medical Association Bremen (Bremen Ost), Medical Univer-
sity of Graz (Graz), Ulm University (G€unzburg) and Medical Association
Westfalen-Lippe and Medical Faculty University of M€unster (M€unster).
Study participants are assessed at four points in time, in intervals
of 6 months, hereafter referred to as study visits 1 (T1; baseline), 2 (T2;
16 months), 3 (T3; 112 months), and 4 (T4; 118 months). Additional
visits should be conducted for clinical participants if they are readmit-
ted for inpatient treatment during the study period. Importantly, partic-
ipating individuals are allowed to miss one or more follow-up study
visits without being excluded from the study. At each study visit,
venous blood samples are collected, permitting extraction of biomateri-
als such as DNA, RNA, plasma, and serum. In addition, a comprehensive
set of phenotype data is collected, assessing symptom dimensions,
cognitive function, and self-report measures (Supporting Information
Table 1; Altman, Hedeker, Peterson, & Davis, 1997; American Psychiat-
ric Association, 2002; Angermeyer, Kilian, & Matschinger, 2000; Army
Individual Test Battery, 1944; Aster, Neubauer & Horn, 2006; McGuf-
fin, Farmer, & Harvey, 1991; Grabe et al., 2012; Grof et al., 2002; Haut-
zinger, Keller, & Kühner, 2006; Helmstaedter, Lendt, & Lux, 2001; Kay,
Fiszbein, & Opler, 1987; Konings, Bak, Hanssen, van Os, & Krabben-
dam, 2006; Krüger, Bräunig, & Shugar, 1997; Lehrl, 2005; Margraf,
1994; McGuffin, Farmer, & Harvey, 1991; National Institute of Mental
Health, 1976; Norbeck, 1984; Rammstedt & John, 2007; Rush, Car-
mody, & Reimitz, 2000; Stefanis et al., 2002; Ware, Kosinski, & Keller,
1996; Wittchen & Fydrich, 1997; Young, Biggs, Ziegler, & Meyer,
1978).
2.1.1 | Clinical participants and broad diagnostic groups
Adult patients (18 years), with an ICD-10 life-time diagnosis of SZ
(F20.x), brief psychotic disorder (F23.x), schizo-affective disorder (SZA;
F25.x), BD (F31.x), manic episode (F30.x), or recurrent major depression
(reMDD; F33.x) are identified based on recommendations of the clinical
staff or by querying patient registries of the participating clinical cen-
ters. Eligible individuals are invited to participate in the first study visit
(T1), where, after giving informed consent (see below), their diagnosis
is reassessed within the DSM-IV framework using an adapted version
of the Structured Clinical Interview for DSM-IV; Axis I Disorders
(SCID-I; Wittchen & Fydrich, 1997). Participants with a life-time DSM-
IV diagnosis of SZ (295.10/295.20/295.30/295.60/295.90) or schizo-
phreniform disorder (295.40), brief psychotic disorder (298.8), or SZA
(295.70) constitute the group with predominantly psychotic symptoms,
whereas those with a life-time DSM-IV diagnosis of BD (296.0x/
296.4x/296.5x/296.6x/296.8x) or reMDD (296.3x) constitute the pre-
dominantly affective group. If none of the above DSM-IV diagnoses
can be ascertained, clinical participants are excluded from the study.
Participants must be proficient in German language to enroll in the
study.
2.1.2 | Nonclinical (control) participants
Inhabitants of the catchment areas of G€ottingen and Munich are con-
tacted either by mail, based on address lists acquired from the local Res-
idents’ Registration Office, or by advertisements in public areas and are
invited to participate in the study. Individuals must be proficient in Ger-
man language to enroll in the study. Those included in the study follow
a similar protocol as the clinical participants (see Supporting Information
Table 1). History of affective or psychotic illness is assessed using a
short diagnostic interview for mental disorders (Margraf, 1994).
2.1.3 | Broad informed consent
Before study participation, written informed consent is obtained from
study participants. A special broad informed consent is required from
participants, as the exact research objectives are not specified and both
phenotypic data and biomaterial are to be stored until they are no lon-
ger useful for research (German National Ethics Council, 2004). Accord-
ing to European and German law, such broad informed consent is only
possible if special data protection measures are taken to shield personal
data from unauthorized access (see Section 2.1.5 on data protection).
Participating individuals must explicitly agree to these measures, if they
want to participate in the study. In addition, potential participants must
decide whether they want to be informed about possible incidental
findings that the study may uncover. Collaboration with nonpsychiatric
research disciplines and the possibility to jointly analyze data together
with other researchers or research consortia is explicitly allowed, albeit
only using pseudonymized data. Furthermore, participants are asked to
release medical facilities involved in their prior treatment from doctor–
patient confidentiality, so that information on their past medical
records can be obtained. This serves as an additional source of informa-
tion on their medical history.
2.1.4 | Opt-out
If a participant decides to opt-out after enrolling in the study, two
options exist:
1. Disposal of the participant’s biomaterial and permanent deletion
of all phenotypic data, or
2. All information collected until that point in time will be retained
but irreversibly anonymized.
Data that are already part of scientific analyses at the time of the opt-
out may be used further, regardless of the opt-out, albeit only in ano-
nymized form.
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2.1.5 | Data protection
As we collect sensitive phenotypic data and biomaterials, a data protec-
tion concept was developed (Demiroglu et al., 2012). Briefly, it includes
an array of organizational measures such as pseudonymization to mini-
mize the risk of participant identification and unauthorized transmission
of personal data to third parties. Four different IT components have
been established by the Department of Medical Informatics at the Uni-
versity Medical Center, G€ottingen, Germany (see Supporting Informa-
tion Figure 1):
1. The identity tool, responsible for storing the identifying data and
for generating two different pseudonyms.
2. The administrative tool, for managing study organization, informed
consent, and communication with the study participants (linked to
the identity tool).
3. The phenotype database, containing information collected using
rating scales, questionnaires, and cognitive tests.
4. The biomaterial database for administering the collected biological
samples.
2.1.6 | Interviewers
Interviewers are provided with instructions in written form for all
instruments and each new interviewer is extensively trained in adminis-
tering the phenotyping battery by an experienced interviewer. Depend-
ing on interviewer experience, training includes discussing the
instructions in detail, watching an experienced investigator conducting
a visit and performing a visit under supervision of the latter. In addition,
trainings for all investigators are held on a regular basis.
2.2 | Biological-psychiatric analyses in the PsyCourse
resource
Clinical data presented herein are from a snapshot of the phenotype
database taken on September 19th, 2016 and include a total of 891
clinical participants. Regarding biomaterial, venous blood samples were
collected at each study visit. Briefly, DNA, RNA, and plasma and serum
samples were prepared using standard methods. Data were analyzed
using R (www.r-project.org, version 3.3.2), and SPSS (IBM, version 24).
2.2.1 | Phenotype analyses
Cross-sectional phenotype data were analyzed with Pearson’s chi-
squared and t tests, depending on the type of data (see Table 1). Longi-
tudinal data were analyzed using linear mixed-effect regression (R
package lme4; Bates, Maechler, Bolker, & Walker, 2014). The variables
age at first study visit, psychiatric treatment at first study visit (ordinal
variable with levels “outpatient/no psychiatric treatment” and “in- or
day patient”), sex, group, and time as well as interactions between sex,
group, and time entered the model as fixed effects. Subject and clinical
center of the first study visit were modeled as random intercept
effects. To fulfill the requirement of normally distributed residuals, we
transformed data of the inventory of depressive symptomatology (IDS-
C30), the young mania rating scale (YMRS) and the positive and nega-
tive syndrome scale (PANSS) positive score using the natural logarithm.
Subsequent visual inspection of the residuals of each model did not
show any obvious deviation from normality. The ANOVA function in
the R lmerTest package (Kuznetsova, Brockhoff, & Christensen, 2016)
was used to obtain p-values for fixed effects using Satterthwaite’s
approximation of degrees of freedom. p-Values of the four linear
mixed-effect models were false discovery rate (FDR) corrected to
account for Type-I error cumulation resulting from multiple compari-
sons. A coefficient of determination (R2) was calculated for each model
with the R r2glmm package (https://github.com/bcjaeger/r2glmm)
using the Nakagawa and Schielzeth (2013) method.
2.2.2 | Genotyping and imputation of genetic data
DNA samples of 825 clinical participants were genotyped using the Illu-
mina Infinium PsychArray (Illumina), yielding information for approxi-
mately 590,000 genetic markers. More than 10% of these markers are
in genetic loci previously associated with neuropsychiatric disorders.
After standard quality control procedures, genotype imputation was
performed using SHAPEIT2 (https://mathgen.stats.ox.ac.uk/genetics_
software/shapeit/shapeit.html) and IMPUTE2 (http://mathgen.stats.ox.
ac.uk/impute/impute_v2.html; Andlauer et al., 2016; Delaneau, Zagury,
& Marchini, 2012; Howie, Donnelly, & Marchini, 2009). The 1000
Genomes project dataset (http://www.internationalgenome.org/;
Phase 3 integrated variant set) was used as reference panel. Genetic
variants with a poor imputation quality (INFO <0.8) were not included
in downstream analyses.
TABLE 1 Comparisons between patient groups with predominantly affective versus predominantly psychotic disorders on demographic varia-
bles at the first study visit (T1)
Affective Psychotic Test statistic DF P
Female sex, n (%) 178 (48.5) 210 (40.1) 5.89 (v2) 1 .015
Age at first interview, mean (range) 45.4 (18–78) 40.8 (18–73) 5.27 (t) 741.43 <.001
Age at illness onset, mean (range) 33.6 (11–73) 27.9 (7–73) 6.94 (t) 592.21 <.001
Marital status single (never married), n (%) 158 (43.1) 336 (64.1) 37.35 (v2) 1 <.001
Family history of psychiatric illness, n (%) 268 (77.7) 334 (67.1) 10.73 (v2) 1 .001
In- or day patient at first study visit, n (%) 128 (34.9) 312 (59.5) 48.16 (v2) 1 <.001
DF5degrees of freedom.
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2.2.3 | Genomic analysis of population structure
The EIGENSOFT package (smartPCA; Patterson, Price, & Reich, 2006)
was used to model ancestry differences between the study partici-
pants. It uses a principal component analysis based on a pruned subset
of approximately 50,000 autosomal SNPs, after excluding regions with
high linkage disequilibrium.
2.2.4 | Polygenic risk scores
SZ-PRS were calculated with PLINK 1.90 (https://www.cog-genomics.
org/plink/1.9) using the imputed genotypes. Briefly, summary statistics
from the SZ GWAS of the Psychiatric Genomics Consortium (http://
www.med.unc.edu/pgc; Discovery Sample) were used to ascertain risk
variants, their p-values, and associated odds ratios (ORs; Ripke et al.,
2014). For this purpose a clumped training dataset of 102,636 inde-
pendent SNPs available in the aforementioned website (Psychiatric
Genomics Consortium) was used for SZ-PRS calculations. Our imputed
genotyped set had a substantial overlap with the training set (93,700
SNPs; 91.3% overlap). In the sample of the present study (Target Sam-
ple), the number of risk alleles carried by an individual (0, 1, or 2) for
each SNP contributing to the PRS, was multiplied by the logarithm of
the OR for that particular variant according to the results from the Dis-
covery Sample. The resulting values were summed up in an additive
fashion to obtain an estimate of the SZ genetic burden for each individ-
ual at 11 different p-value thresholds (p5*10-8; p .0001; p .001;
p .01; p .05; p .1; p .2; p .3; p .4; p .5; p1). SZ-PRS do
not significantly deviate from normality and were standardized using z-
score transformation. Since two phenotypes (diagnostic group, see Sec-
tion 2.2.5, and follow-up study participation, see Section 2.2.6) were
tested for association with SZ-PRS, all p-values from these logistic
regression models were FDR corrected to account for Type-I error
cumulation resulting from multiple comparisons.
2.2.5 | Polygenic risk score analyses of diagnostic group
Ancestry principal components were calculated specifically for the sub-
sample entering these analyses (for methods see Section 2.2.3) to be
able to correct for potential effects of population substructure. Block-
wise logistic regression analyses were used to estimate the amount of
variation of diagnostic group (predominantly affective versus psychotic
symptoms) explained by z-standardized SZ-PRS at 11 different p-value
thresholds. Potential confounding variables, namely sex, age at base-
line, age2, sex 3 age interaction as well as the first five ancestry princi-
pal components, were entered in the first block. In the second block,
the predictor of interest, the respective z-standardized SZ-PRS, was
added. The reported estimates of change in R2 represent the gain in
Nagelkerke’s R2 by adding SZ-PRS to the model.
2.2.6 | Analyses of follow-up study participation
As described in Section 2.1, study participants are allowed to miss one
or more follow-up study visits without being excluded from the study.
To address the question of selective dropouts in the PsyCourse study,
subjects with baseline data only, hereafter referred to as the dropout
group, were compared to subjects with follow-up data for at least one
timepoint within the 18-month study period, hereafter referred to as
the follow-up group. To assure a valid assignment to these groups in
the ongoing project, the study period of 18 months plus an additional
time of 5 months for data entry were considered. Since the export
from the database was carried out on September 19th, 2016, only sub-
jects with a T1 before October 19th, 2014 were selected for these
analyses (N5678).
Logistic regression (forced entry method) was used to test the effects
of the following phenotypic predictors on group-membership (dropout
group vs. follow-up group): sex, age at baseline, age2, age3 sex interaction,
center, diagnosis, educational status, psychiatric treatment at baseline,
duration of illness, PANSS positive score, PANSS negative score, PANSS
general score, IDS-C30 sum score, YMRS sum score and global assessment
of functioning (GAF). In a second step, blockwise logistic regression analy-
ses were performed to estimate the effects of SZ-PRS for 11 different p-
value thresholds, as explained above. Ancestry principal components were
calculated specifically for the subsample entering these analyses (for meth-
ods see Section 2.2.3) in order to be able to correct for potential effects of
population substructure. The significant phenotypic predictors from the
previous analyses, namely sex, sex3 age interaction and psychiatric treat-
ment at baseline, as well as the first five ancestry principal components
were entered as covariates in the first block. In the second block, the
respective z-standardized SZ-PRS was added as a predictor. Estimates of
change inNagelkerke’s R2 relative to the SZ-PRS are reported.
3 | RESULTS
Here, we report data of a total of N5891 clinical individuals that were
included in the study at baseline (first study visit; T1). Of these
N5891 individuals, 526 (59.0%), 415 (46.6%), and 351 (39.4%) com-
pleted the second, third, and fourth study visit, respectively. Impor-
tantly, individuals can miss one or more follow-up study visits without
being excluded from the study. In such cases, individuals were re-
contacted again before the next scheduled appointment and invited to
continue to participate in the study. Also the numbers above represent
a snapshot of the phenotype database taken on the September 19th,
2016. This means that study participants might still be enrolled in the
study at that time and complete further study visits.
We compare clinical groups with predominantly affective symp-
toms (n5367 individuals [41.2% of total sample]; 294 with Bipolar-I
Disorder, 68 with Bipolar-II Disorder, and 5 with reMDD) to those suf-
fering from predominantly psychotic symptoms (n5524 individuals
[58.8% of total sample]; 424 with SZ, 83 with SZA, 11 with schizophre-
niform disorder and 6 with brief psychotic disorder). Approximately
half of the sample (n5440, 49.8%) was treated as in- or daypatient at
baseline. Information on recruitment numbers from single study centers
is displayed in Supporting Information Table 2.
3.1 | Phenotypic analyses
Cross-sectional comparisons on demographic variables between the two
groups are summarized in Table 1. Participants in the predominantly psy-
chotic group were characterized by a lower proportion of females, a
lower age at baseline, a lower age at illness onset, a higher proportion of
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single (never married) individuals and were more frequently treated as in-
or daypatients compared to the predominantly affective group. In addi-
tion, fewer participants in the predominantly psychotic group reported a
family history of psychiatric illness. Descriptive cross-sectional differences
between sexes are summarized in Table 2. Exemplary, the longitudinal
course of acute depressive (IDS-C30) symptoms over the study period is
shown in Figure 1. Analogously, courses of manic (YMRS) and psychotic
(PANSS Positive Scale) symptoms as well as psychosocial functioning
(GAF) are displayed in Supporting Information Figures 2–4.
Linear mixed model analyses of depressive symptoms (Table 3)
reveal effects of in- or daypatient status at study inclusion (mean IDS-
C30 scores at T1-T4 for in- or daypatients: 14.5, 12.2, 13.5, 12.1 and
outpatients/no psychiatric treatment: 10.7, 11.3, 9.8, 11.0) and sex
(mean IDS-C30 scores at T1–T4 for females: 13.3, 12.2, 12.3, 12.4;
males: 12.1, 11.2, 10.2, 10.6). No other variables were significant.
Manic symptoms (Table 4; for post hoc tests see Supporting Infor-
mation Table 3) were not different between the patient groups after cor-
recting for multiple comparisons (mean YMRS scores at T1–T4: 4.0, 2.5,
2.8, 1.9 [affective group] and 2.4, 1.9, 2.3, 2.1 [psychotic group]). How-
ever, symptoms of mania (Supporting Information Figure 2) differed over
time (mean YMRS scores at T1–T4: 3.0, 2.1, 2.5, 2.1), behaved differently
in diagnostic groups over time andwere independent of in- or daypatient
status at baseline. Psychotic symptoms (Table 5; for post hoc tests see
Supporting Information Table 4) differed both over time (mean PANSS
Positive Scale scores at T1–T4: 12.3, 10.3, 10.4, 10.1) and between diag-
nostic groups (mean PANSS Positive Scale scores at T1–T4: 9.5, 8.5, 8.6,
8.3 [affective group] and 14.2, 11.5, 11.6, 11.1 [psychotic group]).
Regarding symptoms, the most prominent difference between both
diagnostic groups is the magnitude of psychotic symptoms (Supporting
Information Figure 3). In both groups, there is a decrease of impairment
after the baseline assessment and toward the end of the study period.
Analyses of GAF values over time (Table 6; for post hoc tests see
Supporting Information Table 5) revealed effects of in- or daypatient
status, diagnostic group, time and the sex3 diagnostic group interac-
tion. Mean GAF values at T1–T4 (Supporting Information Figure 4)
TABLE 2 Sex-specific descriptive statistics of both clinical groups
at the first study visit (T1)
Female Male
Affective group
n 178 189
Age at first visit, mean (range) 45.2 (21–78) 45.6 (18–76)
Age at illness onset, mean (range) 33.7 (12–73) 33.5 (11–73)
Marital status single
(never married), n (%)
70 (39.5) 88 (47.1)
Family history of psychiatric
illness, n (%)
137 (80.6) 131 (75.3)
In- or day patient, n (%) 59 (33.5) 69 (37.5)
Psychotic group
n 210 314
Age at first visit, mean (range) 43.8 (19–73) 38.9 (18–72)
Age at illness onset, mean (range) 29.0 (12–73) 27.1 (7–65)
Marital status single
(never married), n (%)
100 (47.8) 236 (75.4)
Family history of psychiatric
illness, n (%)
140 (72.5) 194 (65.5)
In- or day patient, n (%) 118 (56.2) 194 (61.8)
FIGURE 1 Violin plots of the course of depressive symptoms, separately for both patient groups. Individual trajectories are plotted in gray
color. The numbers of participants included in this graph (T1–T4, respectively) are: 312, 184, 149, 109 (Affective) and 453, 288, 213, 196
(Psychotic)
BUDDE ET AL. | 7L. 95
29
were: 61.5, 65.9, 65.1, 64.8 (affective group, females); 61.6, 66.5,
65.5, 66.6 (affective group, males); 54.5, 61.5, 61.6, 60.5 (psychotic
group, females); and 52.3, 59.8, 58.8, 56.2 (psychotic group, males).
3.2 | Genetic analyses of population structure
Supporting Information Figure 5 shows the PsyCourse subjects and all
1000 genomes super-populations based on the first two ancestry prin-
cipal components and highlights the European origin of most of the
subjects of the PsyCourse study.
3.3 | SZ-PRS analyses of the diagnostic group
A subset of 771 participants with available SZ-PRS and without missing
data in any of the covariates was analyzed. Approximately 57.3% suffered
from predominantly psychotic symptoms while 42.7% suffered from pre-
dominately affective symptoms. Figure 2 shows changes in Nagelkerke’s
R2 due to effects of the SZ-PRS at 11 different p-value thresholds. Along
with the increase of the SZ-PRS, the odds of being in the predominantly
psychotic group increase. The largest effect was observed for the SZ-PRS
at the p-value threshold of .05 (OR51.28; 95% CI: 1.10–1.50).
TABLE 3 Longitudinal analysis of depressive symptoms (IDS-C30)
SS MS NumDF DenDF F p pFDR
Main effects
Age at first visit 0.09 0.09 1 823.91 0.21 .648 .729
In- or day patient at first visit 16.81 16.81 1 792.37 38.41 <.001 <.001
Sex 2.71 2.71 1 888.67 6.19 .013 .047
Dx group 1.52 1.52 1 812.12 3.47 .063 .162
Time (visit) 1.72 0.57 3 1295.28 1.31 .269 .372
Interaction effects
Sex 3 Dx group 1.11 1.11 1 883.85 2.53 .112 .224
Sex 3 time (visit) 0.76 0.25 3 1308.10 0.58 .630 .729
Dx group 3 time (visit) 3.08 1.03 3 1304.03 2.34 .072 .172
Sex 3 Dx group 3 time (visit) 2.04 0.68 3 1307.70 1.55 .199 .325
R2 for the model was 5.7%, 95% confidence interval [4.6, 8.7]. DenDF5 denominator degrees of freedom; Dx5diagnostic; MS5mean square;
NumDF5numerator degrees of freedom; pFDR5 false discovery rate-corrected p-value; SS5 sum of squares.
TABLE 4 Longitudinal analysis of manic symptoms (YMRS)
SS MS NumDF DenDF F p pFDR
Main effects
Age at first visit 0.79 0.79 1 774.58 1.50 .222 .347
In- or day patient at T1 1.11 1.11 1 771.85 2.10 .148 .253
Sex 2.39 2.39 1 822.08 4.50 .034 .095
Dx group 2.59 2.59 1 748.24 4.88 .028 .083
Time (visit) 11.50 3.83 3 1454.76 7.22 <.001 <.001
Interaction effects
Sex 3 Dx group 0.02 0.02 1 814.37 0.03 .856 .856
Sex 3 time (visit) 1.63 0.54 3 1471.93 1.03 .380 .489
Dx group 3 time (visit) 8.98 2.99 3 1466.84 5.64 .001 .003
Sex 3 Dx group 3 time (visit) 2.84 0.95 3 1471.75 1.79 .148 .253
R2 for the model was 2.5%, 95% confidence interval [0.2, 4.8]. For abbreviations see Table 4.
TABLE 5 Longitudinal analysis of psychotic symptoms (PANSS positive score)
SS MS NumDF DenDF F p pFDR
Main effects
Age at first visit 0.07 0.07 1 848.74 1.24 .267 0.372
In- or day patient at T1 0.57 0.57 1 791.26 10.70 .001 0.004
Sex 0.16 0.16 1 923.94 3.04 .082 0.183
Dx group 3.46 3.46 1 847.05 65.50 <.001 <0.001
Time (visit) 6.70 2.23 3 1424.64 42.26 <.001 <0.001
Interaction effects
Sex 3 Dx group 0.07 0.07 1 919.44 1.28 .258 0.372
Sex 3 time (visit) 0.16 0.05 3 1437.95 0.99 .398 0.493
Dx group 3 time (visit) 0.20 0.07 3 1434.62 1.28 .281 0.375
Sex 3 Dx group 3 time (visit) 0.07 0.02 3 1437.35 0.44 .723 0.766
R2 for the model was 14.6%, 95% confidence interval [12.5, 17.8]. For abbreviations see Table 4.
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3.4 | Analyses of follow-up study participation
Logistic regression was performed in 498 participants without miss-
ing data in the phenotypic predictors, 69.5% of whom had follow-up
data from at least one additional study visit. Detailed results can be
found in Supporting Information Table 6. In the baseline model, that
is, without any information from phenotypic predictors, 69.5% of
the subjects were correctly classified. This rate increased to 73.5%
when demographic and disease related variables (for details see Sec-
tion 2.2.6) were entered in the regression model. Nagelkerke’s R2
for the model was 0.282. Female sex (p5 .01; OR50.12; 95% CI:
0.02–0.65) and inpatient treatment at baseline (p< .01; OR50.32;
95% CI: 0.17–0.60) were significantly associated with decreasing
odds of having follow-up data. The age x sex interaction also had a
significant effect in the model (p5 .049; OR51.04; 95% CI: 1.00–
1.08). While in both female and male participants older age was
associated with increasing odds of having follow-up data, this age
effect was slightly stronger in females.
For the SZ-PRS analyses, a subsample of 613 subjects with SZ-
PRS and completely available covariates was analyzed, 71.9% of whom
had follow-up data. Figure 3 shows changes in Nagelkerke’s R2 due to
effects of the SZ-PRS at 11 different p-value thresholds. As the SZ-
PRSs increase, the odds of being in the follow-up group decrease. This
trend was significant after FDR correction for risk scores at two differ-
ent p-value thresholds. Effect sizes at these two p-value thresholds
were similar (p-value threshold of 0.0001: OR50.79; 95% CI: 0.65–
0.95; p-value threshold of .001: OR50.78; 95% CI: 0.64–0.95).
4 | DISCUSSION
Here, we present and provide an initial characterization of the
PsyCourse study, a transdiagnostic study of the affective-to-
TABLE 6 Longitudinal analysis of GAF values
SS MS NumDF DenDF F p pFDR
Main effects
Age at first visit 249.8 249.8 1 861.39 2.86 .091 .193
In- or day patient at T1 6357.0 6357.0 1 215.18 72.83 <.001 <.001
Sex 207.2 207.2 1 947.67 2.37 .124 .234
Dx group 2820.6 2820.6 1 387.57 32.31 <.001 <.001
Time (visit) 8941.0 2980.3 3 1435.55 34.14 <.001 <.001
Interaction effects
Sex 3 Dx group 466.7 466.7 1 939.32 5.35 .021 .069
Sex 3 time (visit) 74.6 24.9 3 1446.20 0.29 .837 .856
Dx group 3 time (visit) 203.1 67.7 3 1444.13 0.78 .508 .609
Sex 3 Dx group 3 time (visit) 130.7 43.6 3 1445.69 0.50 .683 .745
R2 for the model was 16%, 95% confidence interval [13.9, 19.3]. For abbreviations see Table 4.
FIGURE 2 Effects of SZ-PRS on diagnostic group. p-Values signifi-
cant after FDR correction in blue color (baseline model with covari-
ates only: Nagelkerke’s R25 .091; FDR corrected p-values for the
models with p-value thresholds from 5e-08 to 1: .059, .29, .022,
.022, .022, .022, .022, .024, .022, .022, .022)
FIGURE 3 Effects of SZ-PRS on dropout. p-Values significant
after FDR correction in blue color (baseline model with covariates
only: Nagelkerke’s R250.131; FDR corrected p-values for the mod-
els with a p-value threshold from 5e-08 to 1: .705, .03, .03, .088,
.115, .15, .175, .175, .175, .175, .175)
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psychotic continuum that combines longitudinal deep phenotyping
and dimensional assessment of psychopathology with an extensive
collection of biomaterial. Broad informed consent by the partici-
pants allows this study to serve as a unique future resource for the
interrogation of complex genotype–phenotype relationships. The
combination of both longitudinal and cross-sectional phenotype
assessments expands the horizon of genetic association studies
beyond case–control phenotypes. Data collected in this study will
enable researchers to find variants related to disease phenotypes
within clinical groups, not confined to traditional diagnostic boun-
daries, and serve as starting point for the elucidation of disease
mechanisms which are urgently needed to develop new therapeu-
tics (see Wendland & Ehlers, 2016 for a review).
4.1 | Phenotype analyses of symptom dimensions
over time
4.1.1 | IDS-C30, YMRS, and PANSS positive scores
Dimensional assessment of depressive, manic, and psychotic symp-
toms as well as psychosocial functioning were compared between
predominantly affective and predominantly psychotic disorders
over time to identify hallmarks of the short-term course of severe
mental disorders (Murray et al., 2004). Our analyses highlight mild
depressive symptoms in both clinical groups that do not vary over
time or show different patterns over time according to diagnostic
group. Overall, females had slightly higher depression scores than
men at baseline, an effect also observed in samples containing indi-
viduals suffering from either BD (Parker, Fletcher, Paterson, Ander-
son, & Hong, 2014) or SZ (Abel, Drake, & Goldstein, 2010).
Psychotic symptoms, the symptom dimension that, predictably,
showed the largest difference between diagnostic groups,
decreased in both groups after the first study visit. This may be
interpreted as common treatment effect, as many clinical partici-
pants were treated as in- or day patients at the beginning of the
study. Manic symptom ratings did not vary between diagnostic
groups but showed a different fluctuating pattern over time
between predominantly psychotic and predominantly affective
groups. Similar to symptoms of depression, symptoms of mania
were observed in both diagnostic groups and illustrate symptom
overlap between diagnostic groups. The different behavior over
time of symptoms of mania in the diagnostic groups is thought to
reflect the episodic characteristics of BD (Judd et al., 2002). The sex
effect observed across diagnostic groups in depression scores
(higher IDS-C30 scores in females) has neither been reported for SZ
(Zisook et al., 1999) nor BD (Diflorio & Jones, 2010) and highlights
new findings that may emerge when assessing symptom dimensions
across diagnostic boundaries.
In summary, both mild depressive symptoms and symptoms of
mania were comparable between diagnostic groups, whereas large dif-
ferences in psychotic symptoms were the primary characteristic sepa-
rating both diagnostic groups. Furthermore, we highlight a sex-specific
pattern of more severe symptoms of depression in women suffering
from severe mental disorders.
4.1.2 | Effects on psychosocial functioning
GAF values covary with symptom status by definition, a strong effect
of in- or day patient status is therefore not surprising and does, of
course, not imply causality. In addition, the pronounced difference in
GAF values between diagnostic groups may be attributed to a more
severe load of psychotic symptoms in the predominantly psychotic
group. Analogous to the improvement of psychotic symptoms, we also
interpret the GAF improvement over time in both diagnostic subgroups
as treatment effect. The finding of a statistical interaction between sex
and diagnostic group has been observed before when comparing psy-
chotic and affective illnesses (Gade et al., 2015; Heilbronner et al.,
2016), reflecting psychotic females to have higher GAF scores than
psychotic males, whereas no such sex difference exists in BD.
4.2 | SZ-PRS analyses of diagnostic group
We explored whether SZ-PRS are able to differentiate between pre-
dominantly psychotic versus affective participants in the PsyCourse
study. The results are in line with knowledge of not only an overlapping
(Purcell et al., 2009) but also a specific (Ruderfer et al., 2014) polygenic
background of SZ and BD. Nine of 11 SZ-PRS with different p-value
thresholds significantly explained variability of diagnostic group. As
expected, a higher SZ-PRS increased the odds of being in the “predomi-
nantly psychotic” group. Across the range of SZ-PRS, the explained var-
iation is at about 1% toward a p-value threshold of 1. To put that in
context, when comparing patients and controls, SZ-PRS explain about
7% of case–control status in SZ (Ripke et al., 2014) and about 2% in
BD (Charney et al., 2017; Cross-Disorder Group of the Psychiatric
Genomics Consortium, 2013; Purcell et al., 2009). The observation that
the amount of explained variability in our analysis is not as high as the
effects usually observed when comparing cases and controls is prob-
ably due to the common genetic background of the two groups (Purcell
et al., 2009).
4.3 | SZ-PRS analyses of follow-up participation
In the current snapshot of the database, about 70% of the study partic-
ipants have follow-up data for at least one study visit during the entire
18 months study period. Gender and the treatment at baseline were
associated with dropout. More precisely, being male as well as being
treated as an outpatient at baseline increased the odds of having
follow-up data. An effect of age was only significant in interaction with
sex. While in both female and male participants older age was associ-
ated with increasing odds of having follow-up data, this age effect was
slightly more pronounced in females. Effect sizes of the significant pre-
dictors are small and the rate of correctly classified subjects only
improved by 4% in comparison to the baseline model. However, the
largest effects were observed for in- versus outpatient treatment at
baseline. The selective dropout of hospitalized, hence more severely
impaired, participants must be considered when interpreting longitudi-
nal data from the PsyCourse study.
In the present study, associations between SZ-PRS and dropout
were much lower compared to the findings from Martin et al. (2016) in
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the population-based Avon Longitudinal Study of Parents and Children
(ALSPAC). However, a trend in the expected direction with significant
effects for risk scores at two different p-value thresholds was
observed. Since the current sample of the PsyCourse study is consider-
ably smaller than the ALSPAC sample with nearly 8,000 subjects, the
main reason for the lack of significant findings is presumably lower sta-
tistical power. Nevertheless, the results in the present study appear
promising and, as recruitment is ongoing, analyses may be repeated
using a larger sample in the future. To our knowledge, there is no com-
parable investigation in a clinical sample yet.
4.4 | Limitations of the present study
Here, we present the PsyCourse study and provide an overall charac-
terization of the clinical study sample to illustrate its usefulness in
future biological-psychiatric studies. Therefore, our results are explora-
tory and should to be treated as such. Furthermore, we did not include
medication data in the present analysis. This information will be subject
of future studies of the PsyCourse sample. Furthermore, the limited
follow-up period of 18 months should be considered. While a longer
period of time would be desirable to study the long-term course of
severe mental illnesses, prospective samples of chronic patients suita-
ble for biological studies on disease course are scarce. While we think
that studies on the short-term course will uncover important mecha-
nisms of severe mental disorders, the PsyCourse study can provide a
resource for future longitudinal studies.
4.5 | Resource for collaborations
The PsyCourse study constitutes a unique resource on different levels.
First, the project already created a wealth of phenotypic and biological
data, such as genomic, small RNAome, and methylation data. With
recruitment still ongoing, the sample size will increase over time. The
project constitutes a major contributor to a budding initiative spear-
headed by the German Association for Psychiatry and Psychotherapy
(DGPPN) with the aim of establishing a prospective national cohort of
patients with major psychiatric disorders, the so called “DGPPN cohort”
(Anderson-Schmidt et al., 2013). While not in the public domain, the
PsyCourse study is meant to be available to bona fide researchers all
over the world based on mutually agreed memoranda of understanding.
The Appendix contains a brief outline of our Data Sharing Policy. Sec-
ond, the project is accompanied by continuous development of a meth-
odological and logistical framework for longitudinal research in
biological-psychiatry dealing with issues of practical implementation as
well as ethical and legal aspects (Schwanke, Rienhoff, Schulze, & Nuss-
beck, 2013).
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Supplementary Figures  
 
Supplementary Figure 1. IT components of the PsyCourse study responsible for identifying, managing 
and storing phenotype data and biological samples. 
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Supplementary Figure 2. Violin plots of the course of manic symptoms, separately for both patient 
groups. Individual trajectories are plotted in gray color. The numbers of participants included in this 
graph (T1-T4, respectively) are: 349, 207, 163, 126 (Affective) and 502, 307, 232, 214 (Psychotic). 
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Supplementary Figure 3. Violin plots of the course of psychotic symptoms, separately for both patient 
groups. Individual trajectories are plotted in gray color. The numbers of participants included in this 
graph (T1-T4, respectively) are: 355, 210, 168, 130 (Affective) and 518, 309, 243, 221 (Psychotic). 
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Supplementary Figure 4. Violin plots of the course of psychosocial functioning, separately for both 
patient groups. Individual trajectories are plotted in gray color. The numbers of participants included in 
this graph (T1-T4, respectively) are: 358, 207, 167, 129 (Affective) and 517, 310, 242, 220 (Psychotic). 
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Supplementary Figure 5. Principal Components Analysis of PsyCourse participants and European 1000 
genomes project populations (Legend: AFR: African; AMR: American; EAS: East Asian; EUR: European; 
SAS: South Asian). 
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Supplementary Tables 
Supplementary Table 1. Phenotypes collected in the PsyCourse study. Abbreviations: ALDA-Scale – 
Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder (Grof et al., 
2002); ASRM - Altman Self Rating Mania Scale (Altman, Hedeker, Peterson, & Davis, 1997); BDI-II - Beck 
Depression Inventory II (Hautzinger, Keller, & Kühner, 2006); BFI-10 - Big Five Inventory (Rammstedt & John, 
2007); CAPE – Community Assessment of Psychic Experiences (Konings, Bak, Hanssen, van Os, & Krabbendam, 
2006; Stefanis et al., 2002);  CGI - Clinical Global Impression (National Institute of Mental Health, 1976); CTS - 
Childhood Trauma Screener (Grabe et al., 2012); DSM-IV-TR - Diagnostic and statistical manual of mental 
disorders (4th edition) (American Psychiatric Association, 2002); F/U - follow-up; GAF - Global Assessment of 
Functioning Scale (American Psychiatric Association, 2002); IDS-C30 - Inventory of Depressive Symptomatology 
(30 items, clinician rated; Rush, Carmody, & Reimitz, 2000); LEQ - Life Events Questionnaire (Norbeck, 1984); 
MINI-DIPS - Diagnostisches Kurzinterview bei psychischen Störungen (Margraf, 1994); MSS - Manie-
Selbstbeurteilungsskala (Krüger, Bräunig, & Shugar, 1997); MWT-B - Mehrfachwahl-Wortschatz-Intelligenztest 
(Lehrl, 2005); OPCRIT - Operational Criteria Checklist for Psychotic Illness (McGuffin, Farmer, & Harvey, 1991); 
PANSS - Positive and Negative Syndrome Scale (Kay, Fiszbein, & Opler, 1987);  SCID I - Structured Clinical 
Interview for DSM-IV (Axis I Disorders; Wittchen & Fydrich, 1997); SF-12 - SF-12 Health Survey (Ware, Kosinski, 
& Keller, 1996); VLMT - Verbaler Lern- und Merkfähigkeitstest (Helmstaedter, Lendt, & Lux, 2001); WHOQOL-
BREF - World Health Organization Quality of Life questionnaire (Angermeyer, Kilian, & Matschinger, 2000); 
YMRS - Young Mania Rating Scale (Young, Biggs, Ziegler, & Meyer, 1978). 
Participants   Clinical Non-clinicala 
a) Clinician ratings Timepoint Timepoint 
Section Instrument Focusing on Baseline F/U Baseline F/U 
General 
 Demographics  X X X X 
 
Family history of psychiatric 
illness 
 
X  X  
 Psychiatric history of illness  X  X  
 
Medical data and physical 
impairments 
 
X (Xb) X (Xb) 
 Medication  X X X X 
 ALDA-Scale Response to Lithium   X   
 Tobacco and Alcohol  X X X X 
 Substance abuse/dependence  X X X X 
Diagnosis 
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SCID-I  
(Sections A, B, X, C, D) 
Life-time clinical 
diagnosis according 
to DSM-IV-TR criteria  
X    
 
Parts of MINI-DIPS Screening for 
psychiatric illness 
  X  
General psychopathology 
 
CGI Current severity of 
illness (also 
compared to previous 
ratings) 
X X   
 OPCRIT item 90 Course of disorder  X   
Clinical symptomatology 
 
PANSS Positive and negative 
symptoms 
X X X X 
 
IDS-C30  Depressive 
symptoms 
X X X X 
 YMRS Manic symptoms X X X X 
Level of functioning 
 
GAF Psychosocial 
functioning 
X X X X 
Neuropsychological assessments 
 Trail Making Test Executive functioning X X X X 
 Digit-Symbol-Test Processing speed X X X X 
 
Digit-Span  Verbal working 
memory 
X X X X 
 MWT-B Intelligence screening X  X  
 
VLMT  Verbal learning and 
memory 
 X  X 
43
b) Self-ratings 
Clinical symptomatology 
 
BDI–II Depressive 
symptoms 
X X X X 
 MSS Manic symptoms X X X X 
 ASRM Manic symptoms X X X X 
 
CAPE Psychotic-like 
experiences 
  X  
Quality of life 
 
WHOQOL-BREF Subjective quality of 
life 
X X X X 
 
SF-12 Health related quality 
of life 
  X X 
Environmental factors 
 
LEQ Life events within the 
last 6 months 
X X X X 
Personality 
 
BFI-10 Big Five personality 
traits 
X  X  
Other 
 Religiousness  X  X  
 
Medication adherence  Medication 
adherence over last 7 
days and last 6 
months 
X X   
 
 
CTS Exposure to 
traumatic experiences 
as a child  
 X 
 
 
 
X 
 
ascales used to assess non-clinical (control) subjects , bself-reported weight is assessed at each time point
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Supplementary Table 2. Numbers of participants from each clinical center included in the present analyses. 
Clinical center Number of included participants 
Augsburg 
Bad Zwischenahn 
Bochum 
Bremen Ost 
Eschwege 
Göttingen 
Graz 
Günzburg 
Hildesheim 
Liebenburg 
LMU München 
Lüneburg 
Münster 
Osnabrück 
Rotenburg/Wümme 
Tiefenbrunn 
UMG Göttingen 
Wilhelmshaven 
41 
57 
98 
27 
7 
11 
123 
100 
19 
9 
95 
36 
6 
39 
29 
5 
176 
13 
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Supplementary Table 3. YMRS: Post-hoc tests (least square means) between levels of the Time (Visit) and 
Diagnostic group factors. Abbreviation: CI – 95% confidence interval.  
 Estimate Lower CI Upper CI P 
T1 versus T2 1.18 1.09 1.29 <0.001 
T1 versus T3 1.07 0.97 1.18 0.156 
T1 versus T4 1.21 1.10 1.34 <0.001 
T2 versus T3 0.90 0.82 1.00 0.052 
T2 versus T4 1.02 0.92 1.14  0.663 
T3 versus T4 1.13 1.01 1.27  0.031 
Affective T1 vs. Psychotic T1 1.41 1.23 1.62 <0.001 
Affective T1 vs. Affective T2 
Affective T1 vs. Psychotic T2 
Affective T1 vs. Affective T3 
Affective T1 vs. Psychotic T3 
Affective T1 vs. Affective T4 
Affective T1 vs. Psychotic T4 
Psychotic T1 vs. Affective T2 
Psychotic T1 vs. Psychotic T2 
Psychotic T1 vs. Affective T3 
Psychotic T1 vs. Psychotic T3 
Psychotic T1 vs. Affective T4 
Psychotic T1 vs. Psychotic T4 
Affective T2 vs. Psychotic T2 
Affective T2 vs. Affective T3 
Affective T2 vs. Psychotic T3  
Affective T2 vs. Affective T4 
Affective T2 vs. Psychotic T4 
Psychotic T2 vs. Affective T3 
Psychotic T2 vs. Psychotic T3 
Psychotic T2 vs. Affective T4 
Psychotic T2 vs. Psychotic T4 
Affective T3 vs. Psychotic T3 
Affective T3 vs. Affective T4 
Affective T3 vs. Psychotic T4 
1.34 
1.47 
1.19 
1.36 
1.47 
1.41 
0.95 
1.04 
0.84 
0.97 
1.04 
1.00 
1.10 
0.88 
1.02  
1.09 
1.05 
0.80 
0.92 
1.00 
0.96 
1.15 
1.24 
1.19 
1.18 
1.27 
1.03 
1.16 
1.25 
1.20 
0.81 
0.94 
0.71 
0.86 
0.87 
0.88 
0.93 
0.76 
0.86 
0.92 
0.88 
0.68 
0.81 
0.83 
0.84 
0.96 
1.04 
0.99 
1.53 
1.71 
1.37  
1.60 
1.72 
1.66 
1.11 
1.17 
0.99 
1.09 
1.25 
1.13 
1.30 
1.03 
1.21 
1.30 
1.25 
0.96 
1.05 
1.20 
1.09 
1.38 
1.48 
1.43 
<0.001 
<0.001 
0.020 
<0.001 
<0.001 
<0.001 
0.523 
0.435 
0.042 
0.584 
0.662 
0.987 
0.259 
0.122 
0.851 
0.292 
0.562 
0.015 
0.237 
0.967 
0.527 
0.135 
0.018 
0.064 
Psychotic T3 vs. Affective T4 1.08 0.89 1.31 0.452 
Psychotic T3 vs. Psychotic T4 1.04 0.90 1.19 0.624 
Affective T4 vs. Psychotic T4 0.96 0.79 1.17 0.696 
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Supplementary Table 4. PANSS Positive Score: Post-hoc tests (least square means) between levels of the Time 
(Visit) factor. Abbreviation: CI – 95% confidence interval.      
  
 Estimate Lower CI Upper CI P 
T1 vs. T2 1.13 1.10 1.16 <0.001 
T1 vs. T3 1.12 1.09 1.15 <0.001 
T1 vs. T4 1.17 1.13 1.21 <0.001 
T2 vs. T3 0.99 0.96 1.03 0.728 
T2 vs. T4 1.04 1.00 1.07 0.031 
T3 vs. T4   1.04 1.01 1.08 0.017 
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Supplementary Table 5. GAF: Post-hoc tests (least square means) between levels of the Time (Visit) factor. 
Abbreviation: CI – 95% confidence interval. 
 Estimate Lower CI Upper CI P 
T1 vs. T2 -5.18 -6.29 -4.07 <0.001 
T1 vs. T3 -4.41 -5.63 -3.19 <0.001 
T1 vs. T4 -4.03 -5.34 -2.72 <0.001 
T2 vs. T3 0.77   -0.53 2.07 0.245 
T2 vs. T4 1.15 -0.23 2.54 0.101 
T3 vs. T4 0.38 -1.05 1.82 0.600 
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Supplementary Table 6. Logistic regression of follow-up status on phenotypic variables. B=regression 
coefficient; SE=standard error; coding of dichotomous variables: sex: 0=male, 1=female; treatment at baseline: 
0=outpatient, 1=in/daypatient at first study visit; diagnostic group: 0=predominantly psychotic, 1=predominantly 
affective; outcome: 0=dropout, 1=follow up. N=498; *p<0.05; **p<0.01; Nagelkerke´s R2 = 0.282. 
 
  95% CI for odds ratio 
Included B (SE) Lower Odds Ratio Upper 
Constant 18.774 (11440.497)    
Center     
Augsburg 1.851 (21967.782)  6.369  
Bad Zwischenahn -19.389 (11440.497)  <0.001  
Bochum -19.958 (11440.497)  <0.001  
Bremen Ost -19.063 (11440.497)  <0.001  
Eschwege 0.554 (22526.837)  1.740  
Göttingen -20.575 (11440.497)  <0.001  
Günzburg -20.216 (11440.497)  <0.001  
Graz -19.891 (11440.497)  <0.001  
Hildesheim -20.439 (11440.497)  <0.001  
Lüneburg -20.005 (11440.497)  <0.001  
Liebenburg -0.074 (18877.144)  0.929  
München -19.930 (11440.497)  <0.001  
Osnabrück -20.145 (11440.497)  <0.001  
Rotenburg -18.140 (11440.497)   <0.001  
Tiefenbrunn -19.065 (11440.497)  <0.001  
UMG Göttingen -18.847 (11440.497)  <0.001  
Other variables     
Sex (female) -2.089 (0.845)* 0.024 0.124 0.648 
Age at baseline 0.076 (0.058) 0.963 1.079 1.209 
Age2 -0.001 (0.001) 0.998 0.999 1.001 
Age*Sex 0.038 (0.019)* 1.000 1.038 1.078 
Diagnostic group (affective) 0.222 (0.320) 0.667 1.249 2.338 
Educational status 0.022 (0.080) 0.874 1.022 1.196 
In- or day patient at first study visit -1.136 (0.319)** 0.172 0.321 0.600 
Duration of illness 0.012 (0.014) 0.985 1.012 1.040 
PANSS positive score 0.004 (0.035) 0.937 1.004 1.076 
PANSS negative score 0.045 (0.028) 0.990 1.046 1.105 
PANSS general score -0.004 (0.026) 0.946 0.996 1.049 
IDS-C30 sum score -0.010 (0.015) 0.961 0.990 1.019 
YMRS sum score -0.012 (0.026) 0.939 0.988 1.041 
GAF -0.001 (0.012) 0.976 0.999 1.022 
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Abstract 
Genome-wide association studies of case-control status have advanced the understanding of the 
genetic basis of psychiatric disorders. Further progress may be gained by increasing sample size 
but also by new analysis strategies that advance the exploitation of existing data, especially 
for clinically important quantitative phenotypes. The f unctionally- i nformed e fficient r egion- 
based test s trategy (FIERS) introduced herein uses prior knowledge on biological function and 
dependence of genotypes within a powerful statistical framework with improved sensitivity 
and specificity for detecting consistent genetic effects across studies. As proof of concept, 
FIERS was used for the first genome-wide single nucleotide polymorphism (SNP)-based inves- 
tigation on bipolar disorder (BD) that focuses on an important aspect of disease course, the 
functional outcome. FIERS identified a significantly associated locus on chromosome 15 (hg38: 
chr15:48965004 – 49464789 bp) with consistent effect strength between two independent stud- 
ies ( GAIN/TGen : European Americans, BOMA : Germans; n = 1592 BD patients in total). Protec- 
tive and risk haplotypes were found on the most strongly associated SNPs. They contain a CTCF 
binding site (rs586758); CTCF sites are known to regulate sets of genes within a chromatin 
domain. The rs586758 – rs2086256 – rs1904317 haplotype is located in the promoter flanking re- 
gion of the COPS2 gene, close to microRNA4716, and the EID1, SHC4, DTWD1 genes as plausible 
biological candidates. While implication with BD is novel, COPS2, EID1 , and SHC4 are known 
to be relevant for neuronal differentiation and function and DTWD1 for psychopharmacological 
side effects. The test strategy FIERS that enabled this discovery is equally applicable for tag 
SNPs and sequence data. 
© 2018 The Author(s). Published by Elsevier B.V. This is an open access article under the CC 
BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
1. Introduction
For years, collaborative consortia have vastly increased 
sample sizes for genome-wide association studies (GWAS). 
However, worldwide sample size is finite, and data on clin- 
ically important quantitative phenotypes is currently lim- 
ited, largely due to high costs of deep phenotyping and 
lacking harmonization of assessment scales and conditions 
across studies. Nevertheless, quantitative phenotypes are 
especially valuable for understanding underlying biologi- 
cal mechanisms and between-patient heterogeneity. Hence, 
complementary to increasing sample size, new approaches 
and strategies that advance the exploitation of existing 
genome-wide data are highly desirable. 
To gain power and identify underlying mechanisms, re- 
cently single-marker tests have been replaced by joint 
statistics on biological units ( Subramanian et al., 2005; 
Wang et al., 2007 ). Joint statistics greatly reduce the 
multiple-testing burden and may increase power by ag- 
gregating association signals from multiple functionally- 
related loci. Many pioneering approaches have aggregated 
single-SNP GWAS p -values into enrichment statistics for 
genes or pathways ( Wang et al., 2010 ). However, unbiased 
scoring often necessitates time-consuming permutation 
procedures, since genes and pathways differ in numbers of 
SNPs, gene length, gene number and linkage disequilibrium 
(LD)-patterns. Alternatively, SNPs may be aggregated into 
polygenic risk scores that serve for association testing or 
trait prediction ( Dudbridge, 2013 ). Risk scores reduce the 
model space: they collapse multiple SNPs into a single score 
with a priori assumptions on the selection and weighting of 
contributing SNPs ( Dudbridge, 2013 ). A third set of meth- 
ods provide actual joint tests of SNPs at the individual- 
data level. Among them, the kernel score test SKAT ( Schaid, 
2010 ) is very powerful for a broad range of genetic ar- 
chitectures, computationally convenient, and yields exact 
p -values. 
Whereas LD is a nuisance for most statistics, SKAT can 
exploit LD to increase power compared to single-marker 
tests ( Schifano et al., 2012 ) to the extent that testing LD- 
blocks with SKAT is especially powerful ( Malzahn et al., 
2016 ). Since SKAT is a joint test, power increases with cu- 
mulative association strength and the ratio between sam- 
ple size and number of jointly tested SNPs. Therefore, tag 
SNPs may provide higher power than a denser common SNP 
panel of the same region ( Malzahn et al., 2014 ). Whereas 
association strengths and available sample sizes depend 
on studied phenotypes, sizes of tested SNP sets are the 
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analysts’ choice. Of all 284 human pathways listed in the 
KEGG ( Kanehisa and Goto, 2000 ) database at the time of 
download, only 9.5% contained fewer than 500 SNPs of a typ- 
ical GWAS marker panel, but 47% of the pathways contained 
more than 2000 SNPs, and the longest pathway contained 
around 14,500 SNPs. For clinically important phenotypes 
however, primary studies or even worldwide samples with 
comparable phenotyping may encompass only a few thou- 
sand subjects. In these instances, power likely differs pro- 
foundly between short and long pathways, whereas smaller 
biological units provide stable power. Note also that path- 
ways may share genes and genes may share SNPs, thus yield- 
ing partially overlapping test sets. Herein, we leverage the 
observed enrichment of small p -values across GWAS among 
SNPs linked with specific functional elements ( Schork et al., 
2013 ). We a priori identify and test only LD-blocks contain- 
ing specific functional SNPs, considering these regions pu- 
tatively relevant in a hypothesis-driven GWAS. A variety of 
classes of putative functionality of SNPs may be used for 
selecting genomic regions of interest a priori . Herein, we 
chose to use non-synonymous coding SNPs (nsSNPs) and no 
other functional information, as currently nsSNPs can be 
most reliably predicted ( Li and Wei, 2015; Saunders and 
Baker, 2002 ) and many genes implicated with BD suscep- 
tibility ( Hou et al., 2016 ), the disorder of interest herein, 
are protein coding. Hence the presented analysis focused on 
LD-blocks that overlap with protein-coding sections of the 
genome, with the extension that exploiting LD putatively 
may include additional information from SNPs with other 
functionalities as well. The testing of LD-blocks fully capi- 
talizes on SKAT’s advantages. In addition, we improved sen- 
sitivity and specificity to detect consistent genetic effects 
across studies by employing an extension of SKAT ( Malzahn 
et al., 2014 ) for cross-study analysis of individual-level data 
(mega-analysis). 
As proof of concept, we demonstrate the success of this 
f unctionally- i nformed e fficient r egion-based test s trategy 
(FIERS) to uncover genetic risk factors for functional out- 
come in bipolar disorder (BD) in two independent stud- 
ies, Genetic Information Association Network ( GAIN) ( Smith 
et al., 2009 )/ Translational Genomics Research Institute 
(TGen) study ( Smith et al., 2011 ), United States, and 
the Bonn-Mannheim (BOMA) study ( Cichon et al., 2011; 
Fangerau et al., 2005 ), Germany, comprising 1592 pa- 
tients. BD is among the 20 leading causes of disability 
worldwide ( Vos et al., 2012 ) and genetic factors con- 
tribute to BD susceptibility ( Bienvenu et al., 2011; Charney 
et al., 2017 ). However, functional outcome of BD is highly 
variable. While some patients with a mild course of BD 
experience hardly any restrictions in work or personal re- 
lationships between illness episodes, an estimated 30–60% 
suffer from substantial impairment up to the point of 
disability ( Sanchez-Moreno et al., 2009 ). Apart from se- 
vere socio-economic consequences, impaired functional 
outcome also implies a reduced perceived quality of life 
of patients ( Sum et al., 2015 ). Several socio-demographic, 
clinical and cognitive factors associate with impaired func- 
tional outcome in BD (for an overview see Gade et al., 2015; 
Reinares et al., 2013; Solé et al., 2018 ). The knowledge of 
these factors and of their interplay is critical for optimiz- 
ing individualized treatment ( Reinares et al., 2013 ). Along 
the same line, it is of utmost importance to gain deeper 
insights into the biological underpinnings of between- 
patient heterogeneity of functional outcome of BD. 
Heritability and familial clustering of reduced global 
( Savage et al., 2012; Vassos et al., 2008 ), social ( Schulze 
et al., 2006 ), and occupational ( Potash et al., 2007 ) func- 
tioning in families of patients with schizophrenia ( Savage 
et al., 2012; Vassos et al., 2008 ) or BD ( Potash et al., 
2007; Schulze et al., 2006 ) suggest genetic influences. Fur- 
thermore, Global Assessment of Functioning (GAF; DSM-IV 
Axis V) was lower in healthy carriers of neuropsychiatric 
copy-number-variants compared to non-carriers ( Stefansson 
et al., 2013 ). We present here the first genomic study of 
functional outcome of BD. While BD has an episodic char- 
acter, most patients experience longer times outside of 
severe acute manic or depressive episodes than within. Con- 
sequently, FIERS was employed to analyze GAF assessed 
during outpatient treatment, as important cross-diagnostic 
indicator of overall course and severity of psychiatric 
disorder. 
2. Experimental procedures 
2.1. Study participants 
Data were provided by the GAIN / TGen study, United States 
( Smith et al., 2009, 2011 ), and the BOMA study, Germany 
( Cichon et al., 2011; Fangerau et al., 2005 ). All partici- 
pants gave written informed consent prior to study partic- 
ipation. Study protocols were approved by the respective 
institutional review boards and in accordance with the 1964 
Declaration of Helsinki. For the BOMA sample, summary 
statistics can be accessed via the Psychiatric Genomic 
Consortium ( http://www.med.unc.edu/pgc/ ) and individ- 
ual data by contacting the Institute of Psychiatric Phenomics 
and Genomics, University Hospital, LMU Munich, Germany 
(Thomas G. Schulze). GAIN/TGen data can be obtained by 
contacting the Bipolar Genome Study (John R. Kelsoe). GAIN 
genotypes are also available at the database of Genotypes 
and Phenotypes (phs000017.v3.p1). 
From GAIN/TGen , we analyzed 1081 adults of European 
American ancestry diagnosed with BD according to DSM-IV 
criteria who had GAF scores. GAIN/TGen provided imputed 
genome-wide genotypes (see Smith et al., 2009 , 2011 for 
details). Patient age ranged from 17 to 77 years (mean ± sd: 
43 ± 12 years), duration of illness from 0.5 to 64 years 
(mean ± sd: 24 ± 13 years), and 34.9% ( n = 377) of par- 
ticipants were men. Diagnoses were obtained based on the 
Diagnostic Interview for Genetic Studies (DIGS) ( Nurnberger 
et al., 1994 ) and review of available family history and med- 
ical records through a best estimate procedure. 
BOMA participants had minimal illness duration of 6 
months and were recruited for the purpose of genetic stud- 
ies ( Fangerau et al., 2005 ) from consecutive hospital admis- 
sions at the Central Institute of Mental Health, Mannheim 
and the Department of Psychiatry, University of Bonn, Ger- 
many. Diagnoses were established by the German version of 
the Structured Clinical interview for DSM-IV-TR Axis I Disor- 
ders (Diagnostic and Statistical Manual of Mental Disorders, 
4th ed, text revision, SCID-I) ( First et al., 2002; Wittchen 
and Fydrich, 1997 ). We analyzed 511 adult inpatients with 
a lifetime-diagnosis of BD according to DSM-IV criteria 
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and available pre-admission GAF scores and genome-wide 
genotypes (Illumina: HumanHap550v3, Human610, Hu- 
man660w) (17). BOMA patient age was comparable to 
GAIN/TGen and ranged from 18 to 78 years (mean ± sd: 
46 ± 13 years), duration of illness was on average shorter 
(ranging from 0.5 to 61 years, mean ± sd: 17 ± 12 years), 
and the proportion of men was higher (45.0%, n = 230). 
2.2. Phenotype 
Functional outcome was assessed by the GAF score (DSM-IV 
Axis V, American Psychiatric Association, 2002 ); details on 
scale development are described elsewhere ( Endicott et al., 
1976; Luborsky, 1962 ). GAF rates the overall psychological, 
social and occupational functioning of a subject on a con- 
tinuum ranging from 1 to 100 ( Luborsky, 1962 ). Poorer func- 
tioning is indicated by lower GAF scores. 
We analyzed GAF in BD outpatients to target course of 
disorder outside acute illness episodes. GAF assessments 
were performed by board-certified psychiatrists or psychol- 
ogists or psychiatry/psychology trainees at advanced stages 
in their postgraduate education. In GAIN/TGen , GAF was an 
average rating over the past (last) month assessed by di- 
rect interview of outpatients. Observed scores ranged from 
5 to 100 with a median score of 61. In BOMA , the GAF score 
represents a pre-admission state right before the “current”
episode for which the patient received clinical treatment at 
the time of study interview. Observed GAF scores in BOMA 
were higher compared to GAIN/TGen and ranged from 25 to 
100 with a median score of 80. 
2.3. Statistical methods – FIERS 
FIERS applied a hypothesis-guided filter on the genome, 
combining two types of prior information: LD structure 
(from independent reference data) and functional knowl- 
edge (from bioinformatic annotation tools). The goal was 
to a priori identify LD-blocks that contain specific func- 
tional elements. In a second step, only these LD-blocks were 
tested for genotype-phenotype association by employing a 
generalization of SKAT ( Malzahn et al., 2014 ) for cross-study 
analysis of individual-level data (mega-analysis, details be- 
low). This comprised the genotypic information of an LD- 
block into a single association test, yielding a single p - 
value per LD-block, respectively. The employed generaliza- 
tion of SKAT was especially powerful since it methodically 
optimally exploited all available information; specifically, 
genomic correlations and consistency (or lack thereof) of 
putative genetic effects across samples. Finally, to gain ad- 
ditional insight, the detected significant LD-block was ex- 
amined in detail by single-SNP and haplotype association 
analyses. 
2.3.1. FIERS – step I: hypothesis-guided LD-based 
selection of genomic regions 
Prior information on nsSNPs and LD were obtained for in- 
dependent population-based reference data from the In- 
ternational Haplotype Map Project (HapMap phase II CEU 
sample – northern and western European ancestry; 2591820 
SNPs, Sabeti et al., 2003 ) and matched to GAIN/TGen and 
BOMA using hg38 SNP-positions obtained with biomaRt (bio- 
conductor). A listing of nsSNPs was obtained based on SNP 
rs-identifier numbers from SNPnexus ( Dayem Ullah et al., 
2013 ) as predicted by at least one of the widely accepted 
SIFT ( Kumar et al., 2009 ) or PolyPhen ( Adzhubei et al., 2010 ) 
bioinformatics tools ( Friedrichs et al., 2016 ), and irrespec- 
tive of predicted nsSNP impact as this may vary across tran- 
script isoforms. The hg38 start and end positions of LD- 
blocks that contain these functionally annotated SNPs were 
determined using the default algorithm of Haploview 4.2 
( Barrett et al., 2005 ) such that within assigned LD-blocks 
at least 70% of all SNP pairs had D’ estimates with lower 
95% confidence limits above 0.5. The rationale was to de- 
tect reasonably strongly correlated SNP sets for subsequent 
combined evaluation ( Malzahn et al., 2016 ). 
GAIN/TGen and BOMA samples were genetically homoge- 
neous and indistinguishable in the four most important prin- 
cipal components (multidimensional scaling analysis, PLINK, 
data not shown; see Table 1 and Fig. 2 [symbols in bottom 
panel] for high cross-study similarity of estimated variant 
frequencies and SNP correlations). Combining external LD 
information with nsSNP data identified 2957 LD-based blocks 
for association testing (containing 51,382 SNPs in total) from 
410,943 common SNPs available in GAIN/TGen and BOMA af- 
ter quality control. SNPs were directly typed ( BOMA : Hardy- 
Weinberg equilibrium p -value ≥ 10 −5 , call rate ≥ 95%) or 
came from a larger imputed panel ( GAIN/TGen , see Smith 
et al., 2009 , 2011 for details on genotyping, quality con- 
trol and imputation). By construction, GWAS marker panels 
are LD-pruned. Nevertheless, substantial amounts of LD re- 
main and test strategy FIERS exploits this. The two largest 
tested LD-based blocks contained 430 and 186 SNPs; all 
other blocks contained fewer than 79 SNPs. With regards to 
nsSNP content, 72% of the tested LD-based blocks contained 
a single nsSNP, 28% contained at least two, with a maximum 
of 26 nsSNPs in a block. 
2.3.2. FIERS – step II: region-based cross-study analysis 
of individual-level data 
PLINK and R (version 3.2.2) were used for statistical anal- 
yses. All p-values reported are two-sided. Genetic associa- 
tion screening was performed for the full sample ( quanti- 
tative GAF ). Additionally, subjects who had GAF values in 
the lowest versus highest sample quartile were compared 
( GAF extremes ). All analyses were adjusted for fixed ef- 
fects of sex and duration of illness ( Gade et al., 2015 ). Pu- 
tative functional LD-based blocks were tested with SKAT in 
each study ( GAIN/TGen, BOMA ) and in cross-study analyses 
(mega-analysis of individual-level data; quantitative GAF : 
linear model, adjusting for between-study differences of 
GAF values by a random effect ( Malzahn et al., 2014 ); GAF 
extremes : logistic model, adjusting for between-study dif- 
ferences of GAF values by the additional covariate study ). 
Mega-analysis of individual-level data within SKAT assumed 
common SNP effects across studies and a linear kernel on 
minor allele dosages (additive model) with beta -density 
SNP-weights Beta (MAF,0.5,0.5) that depend on the minor 
allele frequency (MAF) of SNPs. This choice of kernel and 
SNP-weights ensured robust power for detecting genetic 
main effects ( Malzahn et al., 2016 ). Mega-analysis increased 
the power ( sensitivity ) for detecting reproducible genetic 
effects as it combined concordant effects across stud- 
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Table 1 GAF in BD outpatients associates with an LD-block on chromosome 15 (hg38: chr15:48965004 – 49464789 bp). 
Position Frequency Effect on quantitative GAF Effect on GAF extremes 
REGION a Single studies Mega analysis Single studies Mega analysis 
Chromosome 15 48965004 – 44 SNPs GER P = 4.9 × 10 −4 P = 1.3 × 10 −5 GER P = 5.4 × 10 −4 P = 5.6 × 10 −6 
49464789 US P = 5.9 × 10 −3 US P = 1.6 × 10 −3 
Top-ranked SNPs within this region b and negatively correlated nsSNP rs11854184 
SNP MA Position Frequency Effect: beta b 95%CI b Meta-analysis Effect: OR b 95% CI b Meta-analysis 
rs4474633 A 48968404 GER 0.316 GER −3.72 [ −5.63, −1.80] P = 4.4 × 10 −5 GER 2.21 [1.47, 3.42] P = 1.3 × 10 −5 
US 0.329 US −1.59 [ −2.93, −0.25] US 1.48 [1.14, 1.93] 
rs11854184 A 49000997 GER 0.199 GER 2.84 [0.54, 5.13] P = 0.013 GER 0.56 [0.33, 0.91] P = 0.013 
US 0.188 US 1.34 [ −0.32, 3.00] US 0.75 [0.54, 1.03] 
rs2413930 T 49083018 GER 0.230 GER −4.12 [ −6.28, −1.97] P = 1.5 × 10 −5 GER 2.26 [1.44, 3.63] P = 5.8 × 10 −6 
US 0.285 US −1.99 [ −3.38, −0.61] US 1.63 [1.23, 2.16] 
rs586758 A 49216375 GER 0.287 GER −3.81 [ −5.80, −1.82] P = 2.5 × 10 −5 GER 2.31 [1.51, 3.62] P = 2.0 × 10 −6 
US 0.297 US −1.84 [ −3.21, −0.47] US 1.63 [1.23, 2.17] 
rs2086256 T 49265829 GER 0.346 GER −3.23 [ −5.13, −1.33] P = 1.1 × 10 −5 GER 2.06 [1.37, 3.16] P = 4.6 × 10 −6 
US 0.348 US −2.27 [ −3.60, −0.94] US 1.62 [1.24, 2.13] 
rs1904317 T 49270069 GER 0.289 GER −3.79 [ −5.77, −1.81] P = 2.5 × 10 −5 GER 2.28 [1.49, 3.56] P = 2.2 × 10 −6 
US 0.297 US −1.84 [ −3.22, −0.47] US 1.63 [1.23, 2.17] 
Six-locus haplotype c rs4474633 – rs11854184 – rs2413930 – rs586758 – rs2086256 – rs1904317 
Haplotype group Position Frequency Effect: beta c 95%CI c Single studies Effect: OR c 95% CI c Single studies 
∗∗∗GCC 48968404 – GER 0.654 GER 3.23 [1.33, 5.13] P = 9.1 × 10 −4 GER 0.49 [0.32, 0.73] P = 6.6 × 10 −4 
49270069 US 0.652 US 2.27 [0.94, 3.60] P = 8.3 × 10 −4 US 0.62 [0.47, 0.81] P = 4.4 × 10 −4 
∗∗∗ATT 48968404 – GER 0.287 GER −3.81 [ −5.80, −1.82] P = 2.0 × 10 −4 GER 2.31 [1.51, 3.62] P = 1.8 × 10 −4 
49270069 US 0.297 US −1.84 [ −3.22, −0.47] P = 8.7 × 10 −3 US 1.63 [1.23, 2.17] P = 6.7 × 10 −4 
∗∗∗GTC 48968404 – GER 0.058 GER 0.86 [ −2.99, 4.72] P = 0.661 GER 0.76 [0.29, 1.93] P = 0.567 
49270069 US 0.051 US −2.36 [ −5.14, 0.42] P = 0.097 US 1.16 [0.68, 1.97] P = 0.587 
CI, confidence interval; GER, German ( BOMA study); MA, minor allele; nsSNP, non-synonymous coding SNP; OR, odds ratio; P, p -value; US, US American Europeans ( GAIN/TGen study). 
a SKAT cross-study mega-analysis of individual-level BOMA and GAIN/TGen data on chromosome 15, hg38: chr15:48965004 – 49464789 bp ( quantitative GAF : linear model, GAF extremes : 
logistic model; adjusted for sex, illness duration, and study; see Methods for details). SKAT-derived p -values ( P ) summarize the joint influence of the available 44 SNPs in this LD-block on 
quantitative GAF and GAF extremes . 
b Displayed are single-SNP analyses of additive minor allele effects on functional outcome for the five most strongly associated SNPs and the enclosed nsSNP rs11854184 in the significant 
LD-block. Analyses within studies are adjusted for sex and illness duration. Studies were meta-analytically combined by Fisher’s p -value pooling. A protective minor allele effect is indicated 
by a positive regression coefficient beta > 0 ( quantitative GAF , linear model) and odds ratio OR < 1 (contrast between GAF extremes , logistic model); beta < 0, OR > 1 for risk minor alleles. 
Minor allele dosages of all five strongly associated SNPs are pairwise strongly positively correlated, and negatively correlated to the minor allele dosage of putative nsSNP rs11854184 . 
c Individual best-estimate haplotypes were nonambiguous on the last three positions and grouped accordingly. The three most frequent haplotype groups had the identifying nucleobase 
combinations GCC, ATT, GTC at rs586758, rs2086256, rs1904317; nucleotide base combinations at rs4474633, rs11854184, rs2413930 varied (indicated by ∗∗∗). For haplotype groups, an 
additive haplotype effect on functional outcome was tested in each study, with adjustment for sex and illness duration. Effects (beta, OR) are specified per haplotype copy. A protective 
haplotype effect is indicated by a positive regression coefficient beta > 0 ( quantitative GAF , linear model) and odds ratio OR < 1 ( GAF extremes , logistic model); beta < 0, OR > 1 for risk 
haplotypes. 
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Fig. 1 Mega-analysis of GAF in German and European American BD outpatients, adjusted for sex and duration of illness. 
Manhattan-like plots display SKAT-derived p -values on the 2957 tested putatively functionally relevant LD-based genomic 
regions (cross-study mega-analysis of individual-level BOMA and GAIN/TGen data). Significance (horizontal line, Bonferroni 
α = 0.05/2,957 = 1.7 × 10 −5 ) was reached for both quantitative GAF and GAF extremes for an LD-block on chromosome 15 
(hg38: chr15:48965004 – 49464789 bp). The dashed vertical line highlights the coinciding location of significance. 
ies into more powerful common effect estimates. Mega- 
analysis also increased specificity since discordant effect di- 
rections across studies will (partially) cancel into small(er) 
average effects, which suppresses their detection. SKAT 
exact p -values were obtained by Davies method ( Davies, 
1980 ). For the 2957 SKAT tests performed, the multiple- 
testing adjusted significance threshold was α = 1.7 × 10 −5 
(Bonferroni). 
2.3.3. FIERS – step III: detailed insight into significant 
regions 
For the 44 SNPs in the detected significant LD-block, single- 
SNP association tests were performed within studies and 
meta-analytically combined between studies by Fisher’s 
p -value pooling ( Fisher, 1925 ). Furthermore, individual best- 
estimate haplotypes on the five most strongly associated 
SNPs and an enclosed nsSNP were determined with PLINK. 
Haplotype association was analyzed within studies assum- 
ing an additive model of the effect of a haplotype or group 
of haplotypes, combining results meta-analytically across 
studies by Fisher’s p -value pooling. 
3. Results 
FIERS tested 2957 putatively relevant LD-based regions. 
Fig. 1 displays Manhattan-like plots of SKAT-derived 
p -values from cross-study mega-analysis of individual-level 
GAIN/TGen and BOMA data. SNP correlations within LD- 
based blocks were subsumed by SKAT tests. Hence SKAT 
tests of LD-based blocks are largely independent of one 
another. The traits quantitative GAF (all subjects) and 
GAF extremes (lowest versus highest study quartile) both 
identified the same significant LD-block on chromosome 15 
(hg38: chr15:48965004 – 49464789 bp; quantitative GAF 
p mega = 1.3 × 10 −5 , GAF extremes p mega = 5.6 × 10 −6 ). 
Of the 44 SNPs contained in this associated LD-block 
(see Supplement for summary statistics), 26 had consistent 
single-SNP effects across studies and meta-analysis p -values 
p meta < 0.05 for both traits (Fisher’s p -value pooling of stud- 
ies). Eighteen of these SNPs even had p -values p study < 0.05 
in both studies and traits ( Fig. 2 , top and middle panel). 
The five top-ranked SNPs ( p meta < 5 × 10 −5 , Table 1 ) 
have strongly positively correlated minor allele dosages 
( r > 0.67); rs586758 and rs1904317 are nearly synonymous 
( r = 0.998). In the vicinity lies a nsSNP (rs11854184); its mi- 
nor allele dosage is negatively correlated with that of the 
five top-ranked SNPs (range = −0.25 > r > −0.34). Individ- 
ual best-estimate haplotypes on these six SNPs (estimated 
with PLINK) were nonambiguous on the last three positions 
and grouped accordingly. This revealed a protective haplo- 
type group ( ∗∗∗GCC, quantitative GAF: p meta = 1.1 × 10 −5 , 
GAF extremes: p meta = 4.6 × 10 −6 ) and a risk haplotype 
group ( ∗∗∗ATT, quantitative GAF: p meta = 2.4 × 10 −5 , GAF 
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Fig. 2 Consistent effect strength across BD outpatient samples. 
In the associated LD-block hg38: chr15:48965004 – 49464789 bp, estimated minor allele effects were consistent across studies (US: 
GAIN/TGen , GER: BOMA ) for quantitative GAF (top, additive effect per minor allele) and GAF extremes (middle, multiplicative 
effect per minor allele; within-study single-SNP analyses, adjusted for sex and illness duration). Results are displayed for 18 SNPs 
that had p -values p study < 0.05 in each study and for nsSNP rs11854184 (square). Sign of effect estimates (risk: beta < 0, OR > 1; 
protective: beta > 0, OR < 1) corresponds to the correlation r of minor allele dosages (bottom panel, solid line) with CTCF binding 
site rs586758 (diamond). The latter is part of the discovered rs586758 – rs2086256 – rs1904317 haplotype (vertical lines, hg38: 
chr15:49216375 – 49270069 bp) and yielded the strongest association evidence among the 5 top-ranked SNPs ( p meta < 5 × 10 −5 , 
Table 1 middle panel). The 5 top-ranked SNPs have strongly positively correlated minor allele dosages ( r > 0.67 bottom panel, 
BOMA : filled symbols, GAIN/TGen : open symbols; square: nsSNP rs11854184). Lines ( D ’: dashed, r : solid) display the highly similar 
LD structure of a CEU reference population (1000 Genomes phase 3, northern and western European ancestry, obtained from 
Ensembl ( Cunningham et al., 2015 , http://www.ensembl.org/ ). 
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extremes: p meta = 2.0 × 10 −6 , Fisher’s p -value pooling of 
studies). Between-study consistency of haplotype associa- 
tion is displayed in Table 1 . A consistent reduction or in- 
crease of the risk of poor GAF, respectively, was also ob- 
served in all members of the two haplotype groups that 
were frequent enough for separate association testing (data 
not shown). 
4. Discussion 
Functional outcome in outpatient care is an important cross- 
diagnostic indicator for course of psychiatric disorder, clin- 
ically highly relevant, and highly variable in BD. To the 
best of our knowledge, this is the first SNP-based inves- 
tigation into the genetic basis of GAF in outpatient care. 
Despite moderate sample size, we identified a significant 
genomic region by introducing the efficient test strategy 
FIERS. Plausibility of our finding on chromosome 15 (hg38: 
chr15:48965004 – 49464789 bp) is supported by consistency 
of effect strength between independent BD patient samples 
( Fig. 2 ) and between genotyped ( BOMA ) and imputed SNPs 
( GAIN/TGen ). Moreover, further underlining plausibility, the 
association evidence centers at a functional SNP, and the as- 
sociated region overlaps with and lies in the vicinity of genes 
that are relevant for neuronal differentiation and function 
(see below). 
Single-SNP and haplotype analyses indicate that nsSNP 
rs11854184 is not likely responsible for the association. The 
reduced power of rs11854184 compared to the top-ranked 
SNPs ( Table 1 ) cannot sufficiently be explained by its lower 
minor allele frequency. In contrast, rs586758 displayed the 
strongest single-SNP association, was part of the discov- 
ered haplotypes (G/A position) and is a CTCF binding site 
( Cunningham et al., 2015 ). CTCF sites regulate groups of 
genes within a chromatin domain. 
GAF is not a measure of cognition and may deteriorate 
in psychiatric disorder for several reasons as it comprises 
social, occupational, and psychological functioning into a 
single score. Nevertheless, functional outcome and degree 
of cognitive impairment are significantly associated in BD 
and schizophrenia patients ( Bowie et al., 2010 ). Further- 
more, GAF scores and cognitive performance were lower in 
healthy carriers of neuropsychiatric copy-number-variants 
compared to non-carriers ( Stefansson et al., 2013 ). The 
novel associated haplotype reported herein is located in the 
promoter flanking region of the COPS2 gene (COP9 signalo- 
some subunit 2, also known as TRIP15, CSN2, ALIEN ), near 
microRNA4716 as plausible biological candidates. COPS2 is 
involved in cell cycle regulation and DNA repair, mediates 
gene silencing, and participates in modulating hormone re- 
sponse and cell proliferation ( Papaioannou, 2007 ). More- 
over, functional studies demonstrated that COPS2 plays cru- 
cial roles in neuronal differentiation and development as 
well as in maintaining neuronal functions ( Akiyama et al., 
2003; Chaerkady et al., 2011 ). Adjacent to the significantly 
associated LD-block, three additional genes are of inter- 
est: upstream EID1 (EP300 interacting inhibitor of differen- 
tiation 1) which influences synaptic plasticity and memory 
function ( Liu et al., 2012 ) and SHC4 (Src homology 2 domain 
containing family member 4, also known as ShcD ) which 
contributes to the regulation of neuronal function through 
mediation of the tyrosine kinase receptor TrkB downstream 
signaling pathway ( You et al., 2010 ). Downstream, gene 
DTWD1 (DTW domain containing 1) has previously been im- 
plicated in a pharmacogenomics study on side-effects of 
antidepressant treatment ( Clark et al., 2012 ). Hence it is 
conceivable that DTWD1 regulation through CTCF binding 
at rs586758 might alter GAF by altering side-effects of 
psychopharmacological medication and hence medication 
adherence. 
A particular strength of this study is the test strategy. 
FIERS contributes to more powerful analyses of existing 
genome-wide data in general and even enables successful 
genomic analyses of moderately sized samples. Using gen- 
eral prior knowledge on putative function and LD, FIERS 
better focused association screening on relevant parts of 
the genome which greatly reduced the number of statisti- 
cal tests performed. Across GWAS, small p -values are espe- 
cially enriched among SNPs that are in LD with specific func- 
tional elements ( Schork et al., 2013 ). FIERS exploits this by 
jointly testing SNPs within LD-based regions opposed to only 
testing functionally annotated SNPs. Among the variety of 
functional annotations that may be used to select LD-blocks 
a priori, nsSNPs have been most extensively validated so 
far . Currently, SIFT and PolyPhen provide one of the most 
widely accepted and accurate ( Saunders and Baker, 2002 ) 
annotations (nsSNPs) whereas it is still difficult to annotate 
and predict non-coding SNPs ( Li and Wei, 2015 ). Analyzing 
nsSNP-containing LD-blocks focused this analysis on protein- 
coding regions of the genome with the extension that ex- 
ploiting LD putatively included additional information from 
SNPs with other functionalities as well. 
A further strength of this investigation is cross-study 
mega-analysis, i.e. joint analysis of individual-level data 
across studies within SKAT. With appropriate covariate- 
adjustments, mega-analysis uses the data most efficiently 
and yields the greatest power. Mega-analysis within SKAT as- 
sumed concordant SNP effects across studies. This increased 
sensitivity for detecting replicable genetic effects and in- 
creased specificity by suppressing detection of discordant 
effects. In comparison, meta-analysis by Fisher’s p -value 
pooling of separately analyzed covariate-adjusted studies 
was less sensitive and less specific but confirmed the re- 
ported significance on chromosome 15, albeit with lower 
power (data not shown). If mega-analysis should become 
infeasible (e.g., because studies have different covariates 
to accommodate or individual-level data cannot be shared), 
SKAT score statistics may also meta-analytically, i.e. on the 
level of summary statistics, account for between-study con- 
cordance of SNP effects ( Lee et al., 2013 ). 
Mandatory for power of any statistical method is that 
size of the unit of analysis (LD-block, gene, pathway) and 
model complexity (main effects, genetic interactions) are 
appropriate in relation to available sample size. Although 
large from a clinical perspective, available sample size was 
a study limitation. We mastered this challenge by testing 
putatively functionally relevant LD-blocks for main effects. 
For larger samples, natural extensions are analyzing genes 
or pathways and allowing for genetic interactions ( Liu et al., 
2007 ). In general, summary statistics on biological units ei- 
ther use select representative SNPs ( Li et al., 2011 , 2012 ) 
or aggregate association evidence from all contained SNPs. 
Aggregation is easily, exactly, and powerfully accomplished 
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by SKAT on individual-level data. In contrast, tedious cor- 
rections for SNP correlations are required when aggregat- 
ing single-SNP p -values, e.g. by Fisher combination test ( de 
Leeuw et al., 2016; Li et al., 2011 ). Other p -value based 
joint tests such as count-based (SNP-ratio or hypergeomet- 
ric test) and rank-based (Kolmogorov–Smirnov) enrichment 
statistics suffer similar drawbacks as the Fisher combination 
test but with lower power ( de Leeuw et al., 2016 ). Using 
representative SNPs instead of fully aggregating all evidence 
is more powerful only when causal SNPs are greatly outnum- 
bered within tested SNP sets ( Li et al., 2011 ) or when causal 
SNPs cannot share association signals well with other SNPs, 
e.g., due to low minor allele frequency ( Li et al., 2012 ). 
Analogously, single-SNP tests may be more powerful than 
aggregate tests if associations are strong but involve very 
few SNPs only ( Chen et al., 2014 ). Otherwise, SKAT is very 
often among the most powerful methods, and is robustly 
powerful for a broad range of genetic architectures (see be- 
low) ( Chen et al., 2014; Li et al., 2012 ). Since SKAT tests 
combine individual-level information of multiple SNPs and 
their correlations, they exploit most of the information used 
in genotype imputation – without doing imputation ( Howey 
and Cordell, 2014 ). SKAT can also analyze sequence and rare 
variants ( Malzahn et al., 2016; Wu et al., 2011 ). However, LD 
should always be estimated on sufficiently frequent SNPs to 
avoid premature division of LD-blocks. As a self-contained 
test ( de Leeuw et al., 2016 ), SKAT evaluates whether any of 
the jointly tested SNPs associates with a trait of interest. 
Aggregation of associations (multiple loci, pathway effects) 
but also relatively localized yet sufficiently strong associa- 
tions such as polygenes or minor genes within pathways may 
make SKAT significant. This consideration hardly makes a 
difference for the LD-block analyses presented herein. How- 
ever, it highlights that for correct data interpretation, ge- 
netic architectures underlying SKAT significances should be 
examined. 
So far, the success of psychiatric genetics is largely based 
on the strategy of founding large consortia for case-control 
studies. However, data on clinically important quantita- 
tive phenotypes is still limited, largely due to high costs 
of deep phenotyping and lacking harmonization of assess- 
ment scales and conditions across studies. Owing to this, 
a potential limitation of the present investigation is that 
only two independent studies were available. That signif- 
icance was reached in the total sample but not in single 
studies is typical for GWAS which commonly regard con- 
sistency of effect estimates across studies ( Fig. 2 ) as ad- 
ditional conclusive evidence. Nevertheless, our consistent 
finding that rs586758 – rs2086256 – rs1904317 haplotype ATT 
carriers ( BOMA : 49.2% ± 4.3%, GAIN/TGen : 50.6% ± 3.0%) 
have lower GAF values would require additional indepen- 
dent validation. Furthermore, no information on medica- 
tion or medication adherence was available and GAF as- 
sessment differed to some extent between studies. GAF 
was assessed at a time point ( BOMA : pre-admission), or 
averaged over a period ( GAIN / TGen : past month) during 
which the state of illness, although sufficiently remitted 
for outpatient care, may have varied. Statistical analyses 
were adjusted for between-study differences of GAF values. 
Nevertheless, differences of GAF assessment might yield 
phenotypes with slightly different underlying biological 
mechanisms. This may explain why genetic effects in the as- 
sociated region ( Table 1 and Fig. 2 ), while consistent across 
studies, were slightly stronger in the putatively better re- 
mitted BOMA sample compared to GAIN / TGen . 
GAF is an overall rating of a patient’s psychological, social 
and occupational functioning. While clinically highly rele- 
vant and commonly used, a single overall score also presents 
some limitations. Specifically, GAF scores lack information 
regarding which of the three domains was most impaired 
and most decisive for individual overall rating. For exam- 
ple, a suicidal person with well-functioning relationships 
and good performance at his or her job would be assigned 
a very low GAF score. Hence future research may proceed 
by operationalizing functional outcome with a more differ- 
entiated measure like e.g. the functioning assessment short 
test (FAST; Rosa et al., 2007 ). Furthermore, when analyz- 
ing GAF scores, it would be of interest to stratify or adjust 
analyses with respect to concomitant symptom severity. Un- 
fortunately, we did not have sufficient data for this, which 
is a study limitation. 
While low GAF scores may occur in psychiatric patients 
for clinically different reasons, the generality of the GAF 
can also be seen as an advantage: GAF is applicable across 
different psychiatric diagnoses that share a common poly- 
genic background ( Cross-Disorder Group of the Psychiatric 
Genomics Consortium, 2013; Forstner et al., 2017; Purcell 
et al., 2009 ) and could be an indicator of a more general 
resilience/ vulnerability factor. Hence it would be of great 
interest to analyze GAF or other measures of functional out- 
come also in other psychiatric disorders, such as schizophre- 
nia, and jointly in patients with different psychiatric 
disorders. 
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Supplementary Table 1: Summary statistics of the 44 SNPs in the significant region
Effect on quantitative GAF Effect on GAF extremes
Meta-analysis Meta-analysis
SNP CHR Position MA Effect: betaGER Pquantitative GAF, GER Effect: betaUS Pquantitative GAF, US Pquantitative GAF, meta Effect: ORGER PGAF extremes, GER Effect: ORUS PGAF extremes, US PGAF extremes, meta
rs12906122 15 48965004 T -3.41 0.00313 -0.85 0.280 0.00704 1.86 0.00941 1.34 0.0584 0.00468
rs4474633 15 48968404 A -3.72 0.000162 -1.59 0.0199 0.0000439 2.21 0.000225 1.48 0.00398 0.0000133
rs11631087 15 48969988 G -2.07 0.0303 -1.52 0.0232 0.00580 1.63 0.0158 1.33 0.0296 0.00404
rs7173509 15 48979887 T 0.35 0.720 0.29 0.681 0.840 0.92 0.670 0.99 0.914 0.913
rs8037958 15 48987209 A -3.02 0.00153 -1.80 0.00778 0.000147 2.09 0.000495 1.47 0.00399 0.0000279
rs11854184 15 49000997 A 2.84 0.0157 1.34 0.115 0.0132 0.56 0.0217 0.75 0.0801 0.0128
rs7167402 15 49009096 A -2.85 0.00272 -1.80 0.00778 0.000249 2.06 0.000657 1.47 0.00399 0.0000363
rs4457942 15 49016326 T -3.26 0.0979 -3.10 0.0135 0.0101 2.17 0.0666 1.68 0.0419 0.0192
rs8029751 15 49031658 A -2.00 0.0532 -1.19 0.0978 0.0326 1.70 0.0161 1.37 0.0257 0.00364
rs4775798 15 49037239 A -3.59 0.0330 -1.54 0.167 0.0341 2.41 0.0233 1.22 0.354 0.0479
rs7177541 15 49050433 A -2.67 0.0153 -1.05 0.163 0.0174 1.92 0.00559 1.44 0.0155 0.000896
rs10519206 15 49058222 T 1.85 0.0460 1.79 0.00740 0.00306 0.68 0.0466 0.70 0.00624 0.00266
rs11070681 15 49066320 G -3.34 0.00866 -0.81 0.296 0.0179 1.92 0.0125 1.38 0.0393 0.00425
rs2413930 15 49083018 T -4.12 0.000202 -1.99 0.00488 0.0000146 2.26 0.000513 1.63 0.000715 0.00000580
rs2413931 15 49083128 C -3.31 0.00126 -1.70 0.0125 0.000190 1.96 0.00215 1.40 0.0112 0.000279
rs2413932 15 49091284 C 0.89 0.408 -0.10 0.894 0.732 0.82 0.364 1.02 0.908 0.696
rs12148348 15 49104667 C -3.15 0.00217 -1.76 0.0101 0.000258 1.92 0.00268 1.40 0.0122 0.000370
rs11633810 15 49124549 C 2.35 0.0118 1.59 0.0151 0.00172 0.58 0.00631 0.74 0.0233 0.00144
rs3088333 15 49140891 T 0.62 0.595 0.18 0.824 0.840 0.88 0.580 0.91 0.560 0.690
rs12915792 15 49146129 T 0.57 0.730 -1.51 0.270 0.518 0.89 0.739 1.58 0.114 0.292
rs2413935 15 49158747 C 2.55 0.00626 1.95 0.00260 0.000196 0.56 0.00414 0.69 0.00366 0.000183
rs586758 15 49216375 A -3.81 0.000198 -1.84 0.00881 0.0000249 2.31 0.000177 1.63 0.000670 0.00000201
rs17396612 15 49257746 G 0.56 0.620 0.70 0.363 0.561 0.89 0.618 0.82 0.184 0.361
rs2086256 15 49265829 T -3.23 0.000905 -2.27 0.000833 0.0000114 2.06 0.000655 1.62 0.000441 0.00000464
rs1904317 15 49270069 T -3.79 0.000202 -1.84 0.00867 0.0000249 2.28 0.000196 1.63 0.000670 0.00000221
rs16962243 15 49270535 T -3.17 0.00439 -1.11 0.143 0.00527 1.97 0.00399 1.48 0.0103 0.000456
rs11854557 15 49280763 C 2.55 0.00944 2.19 0.00126 0.000147 0.55 0.00517 0.64 0.00126 0.0000840
rs7177959 15 49293782 A 0.57 0.730 -1.54 0.261 0.507 0.89 0.739 1.58 0.114 0.292
rs11635005 15 49309228 T 0.50 0.673 0.008 0.993 0.938 0.90 0.649 0.93 0.660 0.791
rs7179127 15 49311418 T 2.47 0.00796 1.75 0.00716 0.000614 0.57 0.00501 0.73 0.0130 0.000695
rs2078024 15 49329413 G 0.56 0.622 0.53 0.493 0.669 0.89 0.618 0.84 0.232 0.422
rs10851475 15 49333733 A -2.99 0.00194 -1.90 0.00512 0.000124 2.01 0.000984 1.49 0.00305 0.0000411
rs16962414 15 49384692 G 1.40 0.460 -1.81 0.209 0.322 0.60 0.222 1.58 0.128 0.130
rs16962418 15 49392588 T 0.30 0.860 -1.88 0.175 0.435 0.84 0.608 1.64 0.0924 0.218
rs12591300 15 49412544 A 1.88 0.0601 0.97 0.154 0.0527 0.69 0.0765 0.78 0.0686 0.0328
rs1904316 15 49416513 C 1.95 0.0381 1.38 0.0332 0.00972 0.61 0.0169 0.73 0.0168 0.00260
rs1429555 15 49419900 A 1.10 0.531 -0.13 0.918 0.838 0.66 0.294 1.03 0.894 0.614
rs12592277 15 49436562 A 0.58 0.599 0.25 0.755 0.811 0.91 0.656 0.93 0.631 0.779
rs4316697 15 49437728 A -2.82 0.00524 -1.84 0.00933 0.000535 1.94 0.00265 1.51 0.00291 0.0000986
rs7168316 15 49441549 T 0.42 0.705 0.32 0.685 0.834 0.89 0.595 0.92 0.597 0.723
rs4338740 15 49443100 C 0.22 0.836 0.87 0.248 0.533 0.87 0.496 0.84 0.225 0.357
rs11634375 15 49457351 T 0.81 0.424 -0.52 0.444 0.503 0.79 0.240 0.98 0.886 0.542
rs11639111 15 49457538 T 1.96 0.0439 0.24 0.711 0.139 0.77 0.188 0.87 0.299 0.218
rs4480740 15 49463645 A 1.69 0.0871 0.94 0.162 0.0741 0.83 0.346 0.82 0.138 0.194
German BD patients US European BD patients German BD patients US European BD patients
Abbreviations: CHR, chromosome; GER, German (BOMA  study); MA, minor allele; OR, odds ratio; P, p-value; Position, hg38 position on chromosome 15; SNP, single nucleotide polymorphism; US, US American Europeans 
(GAIN/TGen  study).  
Single-SNP analyses of additive minor allele effects on functional outcome in outpatient care (quantitative GAF and GAF extremes ) for the 44 SNPs located in the significant LD-block. Analyses within studies are adjusted for
sex and duration of illness. Studies were meta-analytically combined by Fisher’s p-value pooling. To aid visual inspection of this table, all p-values were rounded to the first three relevant digits. A protective minor allele effect is
indicated by a positive regression coefficient beta>0 (quantitative GAF , linear model) and odds ratio OR <1 (contrast between GAF extremes , logistic model); beta<0, OR>1 for risk minor alleles. Eighteen SNPs had p-values
pstudy<0.05 in both studies (GER: BOMA , US: GAIN/TGen ) and both traits (quantitative GAF and GAF extremes ); the sign of estimated minor allele effect (risk or protective) corresponds to the sign of the correlation of minor
allele dosage (positive or negative) with CTCF  binding site rs586758 (see Figure 2).
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